

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information  
**Olerup SSP® HLA-B\*15**

**Product number:** 101.516-24/04 – including *Taq* pol.  
 101.516-24u/04u – without *Taq* pol.  
**Lot number:** 9N3  
**Expiry date:** 2026-05-01  
**Number of tests:** 24 tests – Product No. 101.516-24/24u  
 4 tests – Product No. 101.516-04/04u  
**Number of wells per test:** 95+1  
**Storage - pre-aliquoted primers:** dark, between -15°C and -25°C  
 - PCR Master Mix: between -15°C and -25°C  
 - Adhesive PCR seals RT

**This Product Description is only valid for Lot No. 9N3.**

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP®  
 HLA-B\*15 Lot (1L5)**

- The product documentation has been updated for new alleles of IMGT 3.48.0.
- The kit resolution focuses on common and well documented (CWD) alleles<sup>1</sup>.

<sup>1</sup>As described in section Uniquely Identified Alleles.

The HLA-B\*15 specificity and interpretation tables have been updated for the HLA-B alleles described since the previous *Olerup SSP®* HLA-B\*15 lot was made (**Lot No. 1L5**).

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale
12	-	-	Positive control primer pair exchanged for reduced tendency of primer oligomer formation.
19	Modified	-	Modified 5'-primer for improved HLA-specific amplification.
77	-	Exchanged	Exchanged 3'-primer for improved HLA-specific amplification, redundant primers removed.
79	-	Added	3'-primer added from mix 89.
89	Exchanged	Moved	Exchanged 5'-primer, 3'-primer moved to mix 79 for improved HLA-specific amplification.

<sup>1</sup>S. J. Mack, P. Cano, J. A. Hollenbach et al.  
 Common and well-documented HLA alleles: 2012 update to the CWD catalogue. *Tissue Antigens*, 2013, 81, 194–203



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Well **96** contains Negative Control primer pairs, that will amplify the majority of the *Olerup* SSP<sup>®</sup> HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.

The PCR product generated by the positive control primer pair is 200 base pairs.

Length of PCR product	105	200	105	80	75	80	85
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>	<b>36</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-TAC <sup>3'</sup>
							<b>36</b>
							5'-TAT <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>	<b>47</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ACA <sup>3'</sup>
							<b>48</b>
							5'-gCA <sup>3'</sup>
							<b>48</b>
							5'-gCC <sup>3'</sup>
							<b>52</b>
							5'-TgT <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>DRB1</b>				<b>+</b>	<b>+</b>		
<b>DRB3</b>				<b>+</b>	<b>+</b>		
<b>DRB5</b>				<b>+</b>			
<b>DQB1</b>					<b>+</b>		
<b>DPB1</b>						<b>+</b>	
<b>DQA1</b>							<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

## PRODUCT DESCRIPTION

### HLA-B\*15 SSP subtyping

#### CONTENT

The primer set contains 5'- and 3'-primers for identifying the B\*15:01 to B\*15:632 alleles.

#### PLATE LAYOUT

Each test consists of 96 PCR reactions in a 96 well cut PCR plate.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	24
25	26	27	28	29	30	31	32
33	34	35	36	37	38	39	40
41	42	43	44	45	46	47	48
49	50	51	52	53	54	55	56
57	58	59	60	61	62	63	64
65	66	67	68	69	70	71	72
73	74	75	76	77	78	79	80
81	82	83	84	85	86	87	88
89	90	91	92	93	94	95	NC

The 96 well cut PCR plate is marked with ‘HLA-B\*15’ in silver/gray ink.

Well No. 1 is marked with the Lot No. ‘9N3’.

Wells 1 to 95 – HLA-B\*15 high resolution primers.

Well 96 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded. The PCR plates are covered with a PCR-compatible foil.

#### INTERPRETATION

Due to the sharing of sequence motifs between HLA-B alleles, non-HLA-B\*15 alleles will be amplified by some primer mixes. For further details see Specificity Table.

#### UNIQUELY IDENTIFIED ALLELES

All the HLA-B\*15 alleles, i.e. **B\*15:01 to B\*15:632**, recognized by the HLA Nomenclature Committee in April 2022<sup>1,2</sup> will be amplified by the primers in the HLA-B\*15 subtyping kit.

The HLA-B\*15 kit enables separation of the confirmed HLA-B\*15 alleles as listed in the IMGT/HLA database 3.25.0. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-B\*15 alleles is listed below.

The HLA-B\*15 kit also enables identification of many null and alternatively expressed alleles.



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

**Lot-specific information**

The following HLA-B\*15 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix	Alleles	Primer mix
B*15:81, 15:430	82	B*15:166, 15:193	86
B*15:82, 15:256	36	B*15:169, 15:225	87
B*15:92, 15:104, 15:591	52	B*15:202, 15:239, 15:477	90
B*15:120, 15:258N	93	B*15:206, 15:343	50
B*15:142, 15:147, 15:429	78	B*15:208, 15:230	70
B*15:146, 15:441	75	B*15:301, 15:302N	64

The HLA-B\*15 primer set cannot separate the following alleles. These alleles can be distinguished by the HLA-B low resolution kit and/or the respective high resolution kits:

**Alleles**

B\*15:180, 46:71, 46:89  
 B\*15:515, 35:43:01, 35:135, 35:185, 51:220

<sup>1</sup>HLA-B alleles listed on the IMGT/HLA web page 2022-April-19, release 3.48.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.



0197

101.516-24/04 – including *Taq* polymerase, IFU-01  
101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

### ALLELE CONFIRMATION STATUS

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
B*15:01:01:01	Confirmed	B*15:02:09	Unconfirmed	B*15:18:01:01	Confirmed	B*15:54	Confirmed
B*15:01:01:02N	Confirmed	B*15:02:10	Unconfirmed	B*15:18:01:02	Unconfirmed	B*15:55	Confirmed
B*15:01:01:03	Unconfirmed	B*15:02:11	Unconfirmed	B*15:18:02	Confirmed	B*15:56	Confirmed
B*15:01:01:04	Confirmed	B*15:03:01:01	Confirmed	B*15:18:03	Confirmed	B*15:57	Unconfirmed
B*15:01:01:05	Confirmed	B*15:03:01:02	Confirmed	B*15:18:04	Confirmed	B*15:58	Confirmed
B*15:01:02	Confirmed	B*15:03:02	Confirmed	B*15:18:05	Unconfirmed	B*15:60	Unconfirmed
B*15:01:03	Unconfirmed	B*15:03:03	Confirmed	B*15:18:06	Unconfirmed	B*15:61	Confirmed
B*15:01:04	Unconfirmed	B*15:03:04	Confirmed	B*15:19	Confirmed	B*15:62	Confirmed
B*15:01:06	Confirmed	B*15:03:05	Confirmed	B*15:20	Confirmed	B*15:63	Confirmed
B*15:01:07	Unconfirmed	B*15:03:06	Unconfirmed	B*15:21	Confirmed	B*15:64:01	Confirmed
B*15:01:08	Unconfirmed	B*15:04:01:01	Confirmed	B*15:23	Confirmed	B*15:64:02	Confirmed
B*15:01:09	Confirmed	B*15:04:01:02	Unconfirmed	B*15:24:01	Confirmed	B*15:65	Unconfirmed
B*15:01:10	Confirmed	B*15:04:02	Confirmed	B*15:24:02	Unconfirmed	B*15:66	Unconfirmed
B*15:01:11	Confirmed	B*15:04:03	Unconfirmed	B*15:25:01	Confirmed	B*15:67	Confirmed
B*15:01:12	Unconfirmed	B*15:04:04	Confirmed	B*15:25:02	Confirmed	B*15:68	Confirmed
B*15:01:13	Confirmed	B*15:05:01	Confirmed	B*15:25:03	Unconfirmed	B*15:69	Confirmed
B*15:01:14	Confirmed	B*15:05:02	Confirmed	B*15:26N	Confirmed	B*15:70	Confirmed
B*15:01:15	Confirmed	B*15:06	Confirmed	B*15:27:01	Confirmed	B*15:71	Confirmed
B*15:01:16	Confirmed	B*15:07:01	Confirmed	B*15:27:02	Unconfirmed	B*15:72	Unconfirmed
B*15:01:17	Unconfirmed	B*15:07:02	Unconfirmed	B*15:27:03	Unconfirmed	B*15:73	Confirmed
B*15:01:18	Unconfirmed	B*15:07:03	Confirmed	B*15:28	Unconfirmed	B*15:74	Confirmed
B*15:01:19	Unconfirmed	B*15:08:01	Confirmed	B*15:29	Confirmed	B*15:75	Confirmed
B*15:01:20	Unconfirmed	B*15:08:02	Unconfirmed	B*15:30	Confirmed	B*15:76	Unconfirmed
B*15:01:21	Unconfirmed	B*15:09	Confirmed	B*15:31	Confirmed	B*15:77	Unconfirmed
B*15:01:22	Unconfirmed	B*15:10:01	Confirmed	B*15:32:01	Confirmed	B*15:78:01	Confirmed
B*15:01:23	Unconfirmed	B*15:10:02	Confirmed	B*15:32:02	Unconfirmed	B*15:78:02	Unconfirmed
B*15:01:24	Unconfirmed	B*15:10:03	Unconfirmed	B*15:33	Confirmed	B*15:78:03	Unconfirmed
B*15:01:25	Unconfirmed	B*15:10:04	Unconfirmed	B*15:34	Confirmed	B*15:79N	Unconfirmed
B*15:01:26	Unconfirmed	B*15:11:01	Confirmed	B*15:35	Confirmed	B*15:80	Unconfirmed
B*15:01:27	Unconfirmed	B*15:11:02	Confirmed	B*15:36	Unconfirmed	B*15:81	Unconfirmed
B*15:01:28	Unconfirmed	B*15:11:03	Unconfirmed	B*15:37	Confirmed	B*15:82	Unconfirmed
B*15:01:29	Unconfirmed	B*15:11:04	Unconfirmed	B*15:38:01	Confirmed	B*15:83	Unconfirmed
B*15:01:30	Unconfirmed	B*15:11:05	Unconfirmed	B*15:38:02	Confirmed	B*15:84	Unconfirmed
B*15:01:31	Confirmed	B*15:11:06	Unconfirmed	B*15:39:01	Confirmed	B*15:85	Unconfirmed
B*15:01:32	Unconfirmed	B*15:11:07	Unconfirmed	B*15:39:02	Unconfirmed	B*15:86	Confirmed
B*15:01:33	Unconfirmed	B*15:12	Confirmed	B*15:40:01	Confirmed	B*15:87	Unconfirmed
B*15:01:34	Unconfirmed	B*15:13:01	Confirmed	B*15:40:02	Unconfirmed	B*15:88	Unconfirmed
B*15:01:35	Unconfirmed	B*15:13:02	Unconfirmed	B*15:42	Confirmed	B*15:89	Confirmed
B*15:01:36	Confirmed	B*15:14	Confirmed	B*15:43	Unconfirmed	B*15:90	Unconfirmed
B*15:01:37	Unconfirmed	B*15:15	Confirmed	B*15:44	Unconfirmed	B*15:91	Unconfirmed
B*15:01:38	Unconfirmed	B*15:16:01:01	Confirmed	B*15:45	Confirmed	B*15:92	Unconfirmed
B*15:01:39	Unconfirmed	B*15:16:01:02	Confirmed	B*15:46	Confirmed	B*15:93	Unconfirmed
B*15:02:01	Confirmed	B*15:16:02	Confirmed	B*15:47:01	Confirmed	B*15:94N	Unconfirmed
B*15:02:02	Unconfirmed	B*15:16:03	Unconfirmed	B*15:47:02	Confirmed	B*15:95	Unconfirmed
B*15:02:03	Unconfirmed	B*15:17:01:01	Confirmed	B*15:48	Confirmed	B*15:96	Unconfirmed
B*15:02:04	Confirmed	B*15:17:01:02	Unconfirmed	B*15:49	Unconfirmed	B*15:97	Unconfirmed
B*15:02:05	Unconfirmed	B*15:17:02	Confirmed	B*15:50	Confirmed	B*15:98	Unconfirmed
B*15:02:06	Unconfirmed	B*15:17:03	Unconfirmed	B*15:51	Unconfirmed	B*15:99	Unconfirmed
B*15:02:07	Unconfirmed	B*15:17:04	Unconfirmed	B*15:52	Confirmed	B*15:101	Unconfirmed
B*15:02:08	Unconfirmed	B*15:17:05	Unconfirmed	B*15:53	Confirmed	B*15:102	Unconfirmed



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
B*15:103	Unconfirmed	B*15:154	Confirmed	B*15:202	Unconfirmed	B*15:251	Unconfirmed
B*15:104	Unconfirmed	B*15:155	Confirmed	B*15:203	Unconfirmed	B*15:252	Unconfirmed
B*15:105	Unconfirmed	B*15:156	Unconfirmed	B*15:204	Confirmed	B*15:253	Unconfirmed
B*15:106	Confirmed	B*15:157	Confirmed	B*15:205	Unconfirmed	B*15:254	Unconfirmed
B*15:107	Unconfirmed	B*15:158	Confirmed	B*15:206	Confirmed	B*15:255	Unconfirmed
B*15:108	Confirmed	B*15:159	Confirmed	B*15:207	Confirmed	B*15:256	Unconfirmed
B*15:109	Unconfirmed	B*15:160	Confirmed	B*15:208	Confirmed	B*15:257	Unconfirmed
B*15:110	Unconfirmed	B*15:161	Confirmed	B*15:209N	Unconfirmed	B*15:258N	Unconfirmed
B*15:111N	Unconfirmed	B*15:162	Confirmed	B*15:210	Unconfirmed	B*15:259	Unconfirmed
B*15:112	Unconfirmed	B*15:163	Unconfirmed	B*15:211	Confirmed	B*15:260	Unconfirmed
B*15:113	Confirmed	B*15:164	Unconfirmed	B*15:212	Unconfirmed	B*15:261	Unconfirmed
B*15:114	Unconfirmed	B*15:165	Unconfirmed	B*15:213	Unconfirmed	B*15:262N	Unconfirmed
B*15:115	Unconfirmed	B*15:166	Unconfirmed	B*15:214	Unconfirmed	B*15:263	Confirmed
B*15:116	Unconfirmed	B*15:167	Confirmed	B*15:215	Unconfirmed	B*15:264	Unconfirmed
B*15:117	Unconfirmed	B*15:168	Unconfirmed	B*15:216	Unconfirmed	B*15:265	Unconfirmed
B*15:118	Unconfirmed	B*15:169	Unconfirmed	B*15:217	Unconfirmed	B*15:266	Confirmed
B*15:119	Unconfirmed	B*15:170	Confirmed	B*15:218Q	Unconfirmed	B*15:267	Unconfirmed
B*15:120	Unconfirmed	B*15:171	Confirmed	B*15:219	Unconfirmed	B*15:268	Confirmed
B*15:121	Unconfirmed	B*15:172	Confirmed	B*15:220	Confirmed	B*15:269	Unconfirmed
B*15:122	Unconfirmed	B*15:173	Confirmed	B*15:221	Unconfirmed	B*15:270	Unconfirmed
B*15:123	Unconfirmed	B*15:174	Unconfirmed	B*15:222	Unconfirmed	B*15:271	Confirmed
B*15:124	Unconfirmed	B*15:175	Unconfirmed	B*15:223	Unconfirmed	B*15:272N	Confirmed
B*15:125	Confirmed	B*15:176	Confirmed	B*15:224	Unconfirmed	B*15:273	Unconfirmed
B*15:126	Unconfirmed	B*15:177	Unconfirmed	B*15:225	Unconfirmed	B*15:274	Unconfirmed
B*15:127	Unconfirmed	B*15:178	Unconfirmed	B*15:226N	Unconfirmed	B*15:275:01	Unconfirmed
B*15:128	Unconfirmed	B*15:179:01	Unconfirmed	B*15:227	Unconfirmed	B*15:275:02	Unconfirmed
B*15:129	Unconfirmed	B*15:179:02	Unconfirmed	B*15:228	Confirmed	B*15:276	Unconfirmed
B*15:131	Unconfirmed	B*15:180	Confirmed	B*15:229	Confirmed	B*15:277	Confirmed
B*15:132	Confirmed	B*15:181N	Confirmed	B*15:230	Unconfirmed	B*15:278	Confirmed
B*15:133	Unconfirmed	B*15:182N	Unconfirmed	B*15:231	Unconfirmed	B*15:279	Unconfirmed
B*15:134	Unconfirmed	B*15:183	Confirmed	B*15:232	Confirmed	B*15:280	Unconfirmed
B*15:135	Confirmed	B*15:184	Unconfirmed	B*15:233	Unconfirmed	B*15:281	Unconfirmed
B*15:136	Unconfirmed	B*15:185	Unconfirmed	B*15:234	Unconfirmed	B*15:282	Confirmed
B*15:137	Unconfirmed	B*15:186	Unconfirmed	B*15:235	Confirmed	B*15:283	Unconfirmed
B*15:138	Unconfirmed	B*15:187	Unconfirmed	B*15:236	Confirmed	B*15:284	Unconfirmed
B*15:139	Unconfirmed	B*15:188	Unconfirmed	B*15:237	Confirmed	B*15:285	Confirmed
B*15:140	Unconfirmed	B*15:189	Confirmed	B*15:238	Unconfirmed	B*15:286	Unconfirmed
B*15:141	Confirmed	B*15:190N	Confirmed	B*15:239	Confirmed	B*15:287	Unconfirmed
B*15:142	Confirmed	B*15:191	Unconfirmed	B*15:240	Confirmed	B*15:288	Unconfirmed
B*15:143	Unconfirmed	B*15:192	Unconfirmed	B*15:241	Confirmed	B*15:289	Unconfirmed
B*15:144	Unconfirmed	B*15:193	Unconfirmed	B*15:242:01	Unconfirmed	B*15:290	Confirmed
B*15:145	Unconfirmed	B*15:194	Unconfirmed	B*15:242:02	Unconfirmed	B*15:291	Unconfirmed
B*15:146	Confirmed	B*15:195	Unconfirmed	B*15:243	Unconfirmed	B*15:292	Unconfirmed
B*15:147	Confirmed	B*15:196	Unconfirmed	B*15:244	Unconfirmed	B*15:293	Unconfirmed
B*15:148	Unconfirmed	B*15:197:01	Unconfirmed	B*15:245Q	Unconfirmed	B*15:294N	Unconfirmed
B*15:149N	Unconfirmed	B*15:197:02	Unconfirmed	B*15:246N	Unconfirmed	B*15:295	Unconfirmed
B*15:150	Confirmed	B*15:198	Unconfirmed	B*15:247	Unconfirmed	B*15:296	Unconfirmed
B*15:151	Confirmed	B*15:199	Unconfirmed	B*15:248	Confirmed	B*15:297	Unconfirmed
B*15:152	Unconfirmed	B*15:200	Unconfirmed	B*15:249	Unconfirmed	B*15:298	Unconfirmed
B*15:153	Confirmed	B*15:201	Unconfirmed	B*15:250	Unconfirmed	B*15:299	Unconfirmed



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00



101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
<b>B*15:300</b>	<b>Confirmed</b>	B*15:330	Unconfirmed	B*15:360	Unconfirmed	B*15:390	Unconfirmed
<b>B*15:301</b>	<b>Confirmed</b>	B*15:331	Unconfirmed	B*15:361	Unconfirmed	B*15:391	Unconfirmed
B*15:302N	Unconfirmed	<b>B*15:332</b>	<b>Confirmed</b>	B*15:362	Unconfirmed	B*15:392	Unconfirmed
B*15:303	Unconfirmed	B*15:333	Unconfirmed	B*15:363:01	Unconfirmed	B*15:393	Unconfirmed
B*15:304N	Unconfirmed	B*15:334	Unconfirmed	B*15:364	Unconfirmed	B*15:394	Unconfirmed
B*15:305	Unconfirmed	<b>B*15:335</b>	<b>Confirmed</b>	B*15:365	Unconfirmed	B*15:395	Unconfirmed
B*15:306	Unconfirmed	B*15:336	Unconfirmed	B*15:366	Unconfirmed	B*15:396	Unconfirmed
B*15:307	Unconfirmed	B*15:337	Unconfirmed	B*15:367	Unconfirmed	B*15:397	Unconfirmed
B*15:308	Unconfirmed	B*15:338	Unconfirmed	B*15:368	Unconfirmed	B*15:398	Unconfirmed
B*15:309	Unconfirmed	B*15:339	Unconfirmed	<b>B*15:369</b>	<b>Confirmed</b>		
B*15:310	Unconfirmed	B*15:340	Unconfirmed	B*15:370	Unconfirmed		
B*15:311	Unconfirmed	B*15:341	Unconfirmed	B*15:371	Unconfirmed		
B*15:312	Unconfirmed	<b>B*15:342</b>	<b>Confirmed</b>	B*15:372	Unconfirmed		
B*15:313	Unconfirmed	B*15:343	Unconfirmed	B*15:373	Unconfirmed		
B*15:314	Unconfirmed	B*15:344	Unconfirmed	B*15:374	Unconfirmed		
<b>B*15:315</b>	<b>Confirmed</b>	B*15:345	Unconfirmed	B*15:375N	Unconfirmed		
B*15:316	Unconfirmed	B*15:346	Unconfirmed	B*15:376	Unconfirmed		
B*15:317	Unconfirmed	<b>B*15:347</b>	<b>Confirmed</b>	B*15:377Q	Unconfirmed		
B*15:318	Unconfirmed	B*15:348	Unconfirmed	<b>B*15:378</b>	<b>Confirmed</b>		
<b>B*15:319</b>	<b>Confirmed</b>	B*15:349	Unconfirmed	<b>B*15:379</b>	<b>Confirmed</b>		
B*15:320	Unconfirmed	B*15:350	Unconfirmed	<b>B*15:380N</b>	<b>Confirmed</b>		
B*15:321Q	Unconfirmed	B*15:351	Unconfirmed	B*15:381	Unconfirmed		
B*15:322	Unconfirmed	B*15:352	Unconfirmed	B*15:382	Unconfirmed		
B*15:323	Unconfirmed	B*15:353	Unconfirmed	B*15:383	Unconfirmed		
B*15:324	Unconfirmed	B*15:354	Unconfirmed	B*15:384	Unconfirmed		
B*15:325	Unconfirmed	B*15:355	Unconfirmed	B*15:385	Unconfirmed		
B*15:326	Unconfirmed	B*15:356	Unconfirmed	B*15:386	Unconfirmed		
B*15:327	Unconfirmed	B*15:357	Unconfirmed	B*15:387	Unconfirmed		
B*15:328	Unconfirmed	B*15:358	Unconfirmed	B*15:388	Unconfirmed		
B*15:329	Unconfirmed	B*15:359	Unconfirmed	B*15:389	Unconfirmed		

<sup>1</sup>Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2016-July-14, release 3.25.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

### RESOLUTION IN HOMO- AND HETEROZYGOTES

Results file with resolution in HLA-B\*15 homo- and heterozygotes is available upon request.



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information  
**SPECIFICITY TABLE**

**HLA-B\*15 SSP subtyping**

Specificities and sizes of the PCR products of the 95+1 primer mixes used for HLA-B\*15 SSP subtyping

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA-B*15 alleles <sup>3</sup>	Other amplified Class I alleles
1 <sup>9</sup>	400 bp	800 bp	*15:01:01:01-15:01:04, 15:01:06-15:03:11, 15:03:13-15:07:03, 15:12:01-15:15:01:02, 15:19-15:20, 15:24:01-15:28, 15:30:01:01-15:36, 15:38:01-15:40:02, 15:42-15:43, 15:45-15:50, 15:53-15:55, 15:57-15:58, 15:60-15:65, 15:69-15:71, 15:73:01:01-15:73:01:02, 15:75, 15:77-15:79N, 15:81-15:89:02, 15:91-15:92, 15:94N, 15:96, 15:98, 15:102-15:107, 15:109-15:113, 15:116-15:118, 15:120-15:123, 15:125:01-15:129, 15:131-15:132, 15:135-15:138, 15:140-15:142, 15:144-15:147, 15:150-15:151, 15:154-15:160:01:02, 15:163-15:167, 15:169-15:175, 15:178-15:179:02, 15:181N-15:185, 15:187-15:188, 15:190N, 15:192-15:195, 15:199, 15:201-15:207, 15:210-15:214, 15:217-15:220:04, 15:223-15:225, 15:227-15:228, 15:231-15:235, 15:237, 15:239-15:242:02, 15:244-15:251:03, 15:253, 15:256-15:262:02N, 15:264-15:267, 15:269-15:272N, 15:274, 15:276-15:283, 15:285-15:289, 15:291, 15:295-15:302N, 15:304N, 15:308-15:310, 15:315-15:322, 15:324-15:328, 15:330-15:334, 15:336, 15:339-15:350, 15:352-15:353, 15:355, 15:357-15:360, 15:363:01-15:366, 15:368-15:375N, 15:377Q-15:379, 15:381, 15:383-15:387, 15:389-15:393, 15:395, 15:397-15:402, 15:405-15:407, 15:409-15:410, 15:412-15:413, 15:415-15:419, 15:421-15:422, 15:425, 15:428-15:432, 15:437-15:438, 15:440-15:444, 15:448-15:450, 15:452-15:454N, 15:456-15:461, 15:463N-15:478, 15:480-15:485, 15:488-15:497, 15:499, 15:501-15:502, 15:505, 15:507, 15:510-15:512, 15:514, 15:517-15:522, 15:524-15:525, 15:527-15:529, 15:531, 15:533-15:545, 15:547, 15:549N, 15:551-15:552, 15:554, 15:556-15:562N, 15:564-15:569, 15:571-15:572, 15:574, 15:576-15:593, 15:595-15:601,	*40:12:01-40:12:02, 40:26, 40:40, 40:516, 44:02:68, <b>C*12:301, C*16:85</b>



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00



101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Lot No.: <b>9N3</b>			Lot-specific information	
			15:604N-15:606, 15:608-15:610, 15:614:01:01-15:614:01:02, 15:616Q- 15:618, 15:621, 15:624-15:632	
<b>2<sup>6</sup></b>	290 bp	1070 bp	*15:01:01:01-15:01:03, 15:01:06- 15:01:53, 15:01:55-15:02:12, 15:03:03, 15:04:01:01-15:08:02, 15:10:02, 15:11:01-15:11:03, 15:11:05- 15:15:01:02, 15:17:01:01-15:17:07, 15:19-15:21:01:02, 15:24:01-15:28, 15:30:01:01-15:36, 15:38:01-15:40:02, 15:42-15:46, 15:48, 15:50, 15:55-15:58, 15:60, 15:63, 15:65-15:66, 15:70-15:71, 15:73:01:01-15:73:01:02, 15:75-15:79N, 15:81-15:89:02, 15:92, 15:94N, 15:96- 15:97, 15:101-15:102, 15:104-15:107, 15:109-15:113, 15:116-15:118, 15:120- 15:122, 15:125:01-15:126, 15:128- 15:129, 15:135-15:150, 15:152, 15:154- 15:155, 15:157, 15:159-15:160:01:02, 15:162-15:172, 15:174-15:175, 15:177- 15:179:02, 15:181N-15:185, 15:187- 15:196, 15:199, 15:201-15:209N, 15:211, 15:213-15:219, 15:223-15:225, 15:227-15:228, 15:230-15:234, 15:236- 15:237, 15:239-15:241, 15:244- 15:251:02, 15:256-15:262:02N, 15:264- 15:265, 15:267-15:273, 15:276-15:280, 15:283-15:289, 15:291, 15:295-15:305, 15:308-15:310, 15:315-15:322, 15:324- 15:328, 15:330-15:334, 15:339-15:346, 15:348-15:350, 15:352-15:353, 15:355- 15:361, 15:363:01-15:368, 15:370- 15:375N, 15:377Q-15:378, 15:381, 15:383-15:387, 15:390-15:396, 15:398- 15:407, 15:409-15:413, 15:415-15:417, 15:419-15:425, 15:428-15:432, 15:437- 15:438, 15:440-15:443, 15:446, 15:449- 15:450, 15:452-15:454N, 15:456-15:474, 15:476-15:486, 15:488-15:497, 15:499- 15:501, 15:505, 15:507-15:508, 15:510, 15:512-15:514, 15:516, 15:518-15:525, 15:528N-15:529, 15:531-15:538, 15:540N-15:545, 15:547, 15:549N, 15:551-15:552, 15:554-15:558, 15:561- 15:562N, 15:564-15:569, 15:572, 15:574-15:581, 15:583-15:587, 15:589- 15:601, 15:603-15:606, 15:608-15:609, 15:615, 15:618-15:619, 15:621-15:627, 15:629-15:632	*46:01:01:01-46:70, 46:72-46:76, 46:78-46:88, 46:90-46:96, 51:367, <b>C*01:73, C*03:02:23, C*05:01:28,</b> <b>C*06:02:93, C*07:02:30, C*08:16:02,</b> <b>C*14:02:27</b>
<b>3<sup>4</sup></b>	120 bp	1070 bp	*15:01:01:01-15:01:04, 15:01:06- 15:01:16, 15:01:17 <sup>w</sup> , 15:01:18-15:01:30, 15:01:32-15:01:75, 15:04:01:01- 15:04:04, 15:07:01:01-15:08:02, 15:11:01-15:12:03, 15:14-15:15:01:02,	*07:100, 13:31, 13:41, 13:131, 13:145, 13:164, 18:19, 18:164, 27:25, 27:115, 27:161, 27:245, 35:14:01-35:14:03, 35:43:01, 35:43:03-35:44, 35:62, 35:67, 35:79, 35:86, 35:102, 35:117, 35:135, 35:163, 35:185, 35:213,



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

15:19, 15:24:01-15:24:02, 15:26N-15:28, 35:265, 35:343, 35:390N, 35:413,  
 15:30:01:01-15:30:01:03, 35:475-35:476, 35:512, 35:549, 37:66,  
 15:32:01-15:32:02, 15:34:01- 39:36, 44:146, 44:275, 44:299, 45:05,  
 15:35:01:02, 15:38:01-15:38:02, 15:43, 46:01:01:01-46:02, 46:04-46:05,  
 15:45-15:46, 15:50, 15:53-15:54, 15:56- 46:07N, 46:09-46:10, 46:12, 46:14-  
 15:58, 15:60, 15:63, 15:66, 15:68, 15:70- 46:17, 46:20, 46:22-46:24, 46:26-  
 15:71, 15:73:01:01-15:73:01:02, 15:75- 46:32:02, 46:34-46:42, 46:44, 46:46-  
 15:77, 15:79N, 15:81-15:82, 15:85, 46:53, 46:55N-46:57, 46:60-46:61,  
 15:87, 15:90, 15:92, 15:94N, 15:96- 46:63-46:82, 46:84-46:92, 46:94-  
 15:97, 15:101-15:102, 15:104-15:105, 46:96, 50:47, 51:61:01-51:61:02,  
 15:109-15:111N, 15:113, 15:117-15:118, 51:220, 52:21:01-52:21:02, 52:97,  
 15:120, 15:122, 15:125:01-15:126, 54:06, 54:33, 54:40, 55:21, 56:03,  
 15:128-15:129, 15:135, 15:137, 15:140, 56:43, 57:147, 58:78, **A\*25:66,**  
 15:142-15:149N, 15:152, 15:154, **A\*26:68, A\*26:100, A\*26:200,**  
 15:157, 15:159-15:160:01:02, 15:163- **A\*68:56:01-68:56:02, C\*02:56,**  
 15:167, 15:169, 15:171-15:172, 15:174- **C\*06:20, C\*12:50**  
 15:175, 15:178, 15:180-15:184, 15:187,  
 15:189:01-15:193, 15:201-15:203,  
 15:205-15:207, 15:209N, 15:211-15:212,  
 15:215, 15:217, 15:225, 15:227-15:228,  
 15:231-15:234, 15:236, 15:239, 15:241,  
 15:244-15:247, 15:251:01-15:251:03,  
 15:256-15:262:02N, 15:264, 15:267,  
 15:269-15:270, 15:272N, 15:276-15:280,  
 15:284-15:286, 15:296, 15:298-15:299,  
 15:303-15:305, 15:309, 15:315-15:318,  
 15:320-15:321Q, 15:324, 15:326-15:327,  
 15:331, 15:333-15:334, 15:336, 15:340,  
 15:342-15:344, 15:346-15:347,  
 15:349:01-15:350, 15:353, 15:355,  
 15:359, 15:363:01-15:363:02, 15:365,  
 15:367-15:368, 15:370-15:373, 15:375N,  
 15:377Q, 15:381, 15:385-15:387,  
 15:390-15:392, 15:398, 15:400N-15:401,  
 15:405-15:406, 15:409-15:410, 15:412-  
 15:413, 15:415-15:417, 15:419, 15:422,  
 15:428-15:432, 15:440-15:443, 15:450,  
 15:452-15:453, 15:456-15:457, 15:459,  
 15:461, 15:464-15:467, 15:469-15:474,  
 15:476-15:484, 15:486, 15:488-15:490,  
 15:492-15:493, 15:496N, 15:498-15:499,  
 15:501, 15:507, 15:510, 15:512-15:515,  
 15:520Q-15:522, 15:525, 15:528N-  
 15:529, 15:531, 15:533-15:536, 15:538,  
 15:540N-15:542, 15:545, 15:547,  
 15:549N, 15:551, 15:554, 15:556,  
 15:558-15:559, 15:561-15:562N, 15:565,  
 15:568, 15:572, 15:576, 15:579-15:581,  
 15:583, 15:585-15:586, 15:590-15:591,  
 15:593, 15:595, 15:597-15:598,  
 15:600-15:601, 15:604N-15:606, 15:608-  
 15:609, 15:618, 15:621-15:622, 15:624,  
 15:631-15:632

<b>4</b>	180 bp 390 bp	<b>800 bp</b>	*15:01:01:02N *15:285, 15:378
----------	------------------	---------------	----------------------------------



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.careadx.com](http://www.careadx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Lot No.	Size 1	Size 2	Alleles	Alleles
5 <sup>6</sup>	385 bp	1070 bp	*15:02:01:01-15:02:12, 15:08:01:01-15:11:07, 15:13:01-15:13:03, 15:15:01:01-15:15:01:02, 15:18:01:01-15:18:10, 15:21:01:01-15:21:01:02, 15:23, 15:29:01:01-15:29:01:02, 15:31:01:01-15:31:01:03, 15:37, 15:44, 15:51-15:52, 15:55, 15:64:01-15:64:02, 15:72, 15:76 <sup>w</sup> , 15:80, 15:88-15:90, 15:93, 15:99, 15:108, 15:112, 15:114-15:115, 15:119, 15:121, 15:124, 15:133-15:134, 15:139, 15:143-15:144, 15:148, 15:153, 15:161, 15:170, 15:176, 15:186, 15:189:01-15:189:02, 15:191, 15:194, 15:197:01-15:198, 15:200, 15:209N, 15:213-15:215, 15:221, 15:223, 15:226N, 15:229, 15:238, 15:252, 15:263, 15:265, 15:275:01-15:275:02, 15:283-15:284, 15:290-15:294N, 15:297, 15:301-15:303, 15:305-15:308, 15:311-15:314, 15:319, 15:323, 15:325, 15:328-15:330, 15:335, 15:337-15:338, 15:341, 15:345, 15:350-15:351, 15:354, 15:357-15:358, 15:367, 15:374, 15:378, 15:380N, 15:382, 15:384, 15:388, 15:394, 15:399, 15:404, 15:414, 15:418, 15:420, 15:425-15:427, 15:433-15:439, 15:445, 15:447, 15:451, 15:454N-15:455, 15:460, 15:479, 15:486-15:487N, 15:491, 15:495, 15:498, 15:503-15:505, 15:508, 15:509 <sup>w</sup> , 15:513, 15:526, 15:530, 15:537, 15:548, 15:553, 15:557, 15:563, 15:567, 15:569-15:570, 15:573-15:574, 15:592, 15:596N, 15:607, 15:611-15:612, 15:615, 15:620, 15:622-15:623, 15:627, 15:629-15:630	*51:367, C*06:147, C*12:301
6	525 bp	1070 bp	*15:02:01:01-15:02:12, 15:13:01-15:13:03, 15:21:01:01-15:21:01:02, 15:25:01:01-15:25:04, 15:36, 15:44, 15:62, 15:77, 15:80, 15:85, 15:88-15:89:02, 15:106, 15:112, 15:121, 15:139, 15:144, 15:154, 15:165, 15:170, 15:194, 15:204, 15:213-15:214, 15:223, 15:240, 15:250, 15:265, 15:271, 15:283, 15:289, 15:291, 15:297, 15:301-15:302N, 15:308, 15:319, 15:325, 15:328, 15:330, 15:341, 15:345, 15:357-15:358, 15:366, 15:374, 15:378, 15:393-15:394, 15:399, 15:402, 15:404, 15:407, 15:418, 15:420, 15:425, 15:437-15:438, 15:454N, 15:458, 15:460, 15:463N, 15:468, 15:491, 15:495, 15:505, 15:537, 15:543-15:544N, 15:557, 15:564, 15:566-15:567, 15:569, 15:574, 15:584N, 15:587, 15:589, 15:592,	*46:33, 46:67



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including Taq polymerase, IFU-01  
101.516-24u/04u – without Taq polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Lot No.: <b>9N3</b>		Lot-specific information	
<b>7</b>	330 bp	1070 bp	<p>15:594, 15:596N, 15:599, 15:615, 15:623, 15:625, 15:627, 15:630</p> <p>*15:03:01:01-15:03:13, 15:09:01-15:10:08, 15:18:01:01-15:18:10, 15:23, 15:29:01:01-15:29:01:02, 15:37, 15:46-15:47:02, 15:49, 15:51-15:54, 15:61-15:62, 15:64:01-15:64:02, 15:69, 15:72, 15:74, 15:80, 15:90-15:91, 15:93, 15:98-15:99, 15:103, 15:106, 15:108, 15:114-15:115, 15:119, 15:123-15:124, 15:127, 15:131-15:134, 15:143, 15:151, 15:153, 15:156, 15:158, 15:161, 15:173, 15:176, 15:186, 15:197:01-15:198, 15:200, 15:210, 15:212, 15:220:01:01-15:221, 15:226N, 15:229, 15:235, 15:238, 15:242:01-15:243, 15:252-15:253, 15:255, 15:259, 15:263, 15:266, 15:274-15:275:02, 15:281-15:282, 15:290, 15:292-15:294N, 15:306-15:307, 15:311-15:314, 15:323, 15:329, 15:335, 15:337-15:338, 15:351, 15:354, 15:369, 15:379-15:380N, 15:382, 15:388-15:389, 15:397, 15:414, 15:426-15:427, 15:433, 15:435, 15:439, 15:444-15:445, 15:447-15:448, 15:451, 15:455, 15:475, 15:487N, 15:498, 15:502-15:504, 15:509, 15:511, 15:517, 15:525-15:527, 15:530, 15:539, 15:548, 15:553, 15:560, 15:563, 15:570-15:571, 15:582, 15:588, 15:607, 15:610-15:612, 15:614:01:01-15:614:01:02, 15:616Q-15:617, 15:620, 15:628</p> <p>*27:195, 40:12:01-40:12:02, 40:26, 40:40, 40:516, 44:02:68, <b>C*03:342, C*07:46, C*07:356, C*07:546, C*12:184, C*15:99, C*16:85</b></p>
<b>8<sup>4</sup></b>	105 bp	1070 bp	<p>*15:04:01:01-15:04:04, 15:16:01:01-15:16:05, 15:67, 15:95, 15:137, 15:155, 15:222, 15:254, 15:293, 15:310, 15:362, 15:408, 15:499, 15:517, 15:531, 15:550, 15:602, 15:609, 15:613</p> <p>*13:04, 13:46, 13:72, 13:127, 13:140, 13:160, 35:37, 35:235, 35:265, 35:276, 39:06:01:01-39:06:07, 39:33-39:34, 39:50, 39:57, 39:62, 39:64, 39:83:01-39:83:03, 39:90, 39:102, 39:109, 39:127, 39:129, 39:132, 39:140-39:141, 39:154, 39:178, 39:186-39:187, 40:86, 40:159, 40:330, 41:30, 41:50, 45:02, 45:09, 46:32:01-46:32:02, 49:04:01-49:05:02, 49:50, 50:09, 50:33, 51:13:01-51:13:02, 51:37, 51:63:01-51:63:02, 51:92:01-51:92:02, 51:97, 51:172, 51:216, 51:251, 52:14:01-52:14:02, 52:39, 52:75, 52:97, 54:14, 55:13, 55:23, 55:32, 55:58, 55:68, 56:22, 56:50, 58:122, 59:03, 73:01:01:01-73:03, <b>C*05:152, C*07:463, C*07:758, C*12:183</b></p>
<b>9</b>	365 bp	1070 bp	<p>*15:05:01:01-15:05:03, 15:31:01:01-15:31:01:03, 15:48, 15:51<sup>w</sup>, 15:52, 15:55, 15:84, 15:86, 15:91, 15:107,</p> <p>*46:06, 46:09, 46:11, 46:13:01-46:13:03, 46:18-46:19, 46:21:01-46:21:02, 46:25, 46:33, 46:43</p>



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

			15:114, 15:123-15:124, 15:136, 15:151, 15:155, 15:179:01 <sup>w</sup> -15:179:02 <sup>w</sup> , 15:185-15:186, 15:188, 15:218Q <sup>w</sup> , 15:222, 15:224, 15:235, 15:237, 15:275:01-15:275:02, 15:283, 15:332, 15:348, 15:383, 15:393, 15:396, 15:407, 15:415, 15:421, 15:449, 15:485, 15:499, 15:507, 15:518 <sup>w</sup> , 15:539, 15:552, 15:577, 15:578 <sup>w</sup> , 15:587, 15:599, 15:623, 15:628
<b>10</b>	300 bp 515 bp	1070 bp	*15:37-15:38:02, 15:185, 15:323, 15:335, 15:364, 15:368, 15:435, 15:610 *15:06, 15:27:01:01-15:27:04, 15:84, 15:109, 15:112, 15:195, 15:327, 15:344, 15:398
<b>11</b>	140 bp	<b>800 bp</b>	*15:07:01:01-15:07:03, 15:45, 15:55, 15:68, 15:126, 15:197:02, 15:207, 15:324, 15:329, 15:331, 15:360, 15:383, 15:405, 15:431, 15:450 *07:68:01-07:68:03, 07:100, 07:237, 07:262:01-07:262:02, 07:424, 08:71, 08:274, 08:296, 13:108, 14:05, 14:13, 14:53, 18:14, 27:32, 27:138, 27:180, 35:05:01:01-35:05:06, 35:22:01:01-35:22:01:02, 35:51:01-35:51:02, 35:58, 35:66, 35:72, 35:89, 35:97, 35:199, 35:232, 35:368, 35:389, 35:416, 35:427N, 35:440, 35:459N, 35:472, 35:481, 35:498-35:499, 35:509, 35:519, 35:541, 38:19, 39:03:01:01-39:03:01:03, 39:14:01:01-39:14:01:03, 39:24:01-39:24:03, 39:29, 39:37:01:01-39:37:01:02, 39:76, 39:120, 39:144, 39:152, 39:182, 39:184-39:185, 40:35:01-40:35:03, 40:71, 41:24, 42:10, 42:17, 44:54, 44:106, 44:135, 44:158, 44:184, 44:213, 46:12, 48:12, 48:14, 48:29, 51:64, 53:14, 53:67, 55:110, 58:18
<b>12</b>	400 bp	<b>800 bp</b>	*15:08:01:01-15:08:02, 15:29:01:01-15:29:01:02, 15:49, 15:56, 15:191, 15:236, 15:479, 15:508, 15:553, 15:622 *51:367, <b>C*06:147</b>
<b>13</b>	395 bp	<b>800 bp</b>	*15:09:01-15:10:08, 15:18:01:01-15:18:10, 15:21:01:01-15:21:01:02, 15:23, 15:37, 15:44, 15:51-15:52, 15:66, 15:72, 15:80, 15:90, 15:93, 15:99, 15:108, 15:114-15:115, 15:119, 15:124, 15:133-15:134, 15:153, 15:161, 15:176, 15:186, 15:189:01-15:189:02, 15:197:01-15:198, 15:200, 15:221, 15:226N, 15:229, 15:238, 15:243, 15:252, 15:263, 15:275:01-15:275:02, 15:290, 15:292-15:294N, 15:306-15:307, 15:311-15:314, 15:323, 15:329, 15:335, 15:337-15:338, 15:351, 15:354, 15:376, 15:380N, 15:382, 15:388, 15:394, 15:404, 15:414, 15:420, 15:426-15:427, 15:433-15:436, 15:439, 15:445, 15:447, 15:451, 15:455,



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

	435 bp		15:487N, 15:498, 15:503-15:504, 15:526, 15:530, 15:548, 15:563, 15:570, 15:573, 15:607, 15:611-15:612, 15:615, 15:620, 15:623 *15:79N	
<b>14</b>	465 bp	1070 bp	*15:09:01-15:10:08, 15:30:01:01- 15:30:01:03, 15:37, 15:45, 15:48, 15:63, 15:83:01:01-15:83:01:02, 15:90, 15:99, 15:150, 15:188, 15:243, 15:248, 15:252, 15:287, 15:312-15:313, 15:323-15:324, 15:329, 15:338, 15:361, 15:427, 15:435, 15:439, 15:445, 15:455, 15:503, 15:506, 15:530, 15:541, 15:563, 15:611, 15:620 *15:110	*46:74, 46:81
<b>15<sup>4,6</sup></b>	515 bp 105 bp	1070 bp	*15:01:02, 15:09:01-15:09:02, 15:243, 15:252, 15:277-15:278, 15:361, 15:435	*07:02:11, 07:05:03, 08:274, 18:205, 35:251:01, 40:01:06, 40:26, 41:02:09, 48:01:08, 51:06:01:01-51:06:01:03, 51:06:03-51:06:04, 51:59, 51:64, 51:135, 51:194, 51:293, 51:319, 51:341, 51:352, <b>C*02:02:23</b>
<b>16<sup>4</sup></b>	120 bp 190 bp	1070 bp	*15:116, 15:124, 15:352, 15:412, 15:507 *15:12:01-15:12:03, 15:19, 15:270, 15:298, 15:304N	*35:331, 40:52, 40:59, 40:352, 46:06, 46:43, 48:23, 57:59
<b>17</b>	435 bp	1070 bp	*15:13:01-15:13:03, 15:16:01:01- 15:17:07, 15:23-15:24:02, 15:67, 15:87, 15:95, 15:157, 15:162, 15:168, 15:177, 15:196, 15:208, 15:216, 15:222, 15:230, 15:254, 15:268, 15:273, 15:356, 15:361- 15:362, 15:396, 15:403, 15:408, 15:411, 15:418, 15:423-15:424, 15:442, 15:446, 15:462, 15:500, 15:516, 15:523, 15:532, 15:550, 15:555, 15:575N, 15:586, 15:602-15:603, 15:613, 15:619	*51:367, <b>A*25:01:20</b>
<b>18</b>	195 bp	1070 bp	*15:14, 15:91, 15:131, 15:161, 15:518, 15:551, 15:592	*18:56, 18:169, 35:45, 35:71, 44:17, 44:43:01-44:43:02, 44:144, 44:230, 44:256, 44:308, 45:09, 46:17, 53:22, 57:93, 57:119, 58:07, <b>C*02:82,</b> <b>C*06:165, C*07:979, C*14:61</b>
<b>19</b>	395 bp	<b>800 bp</b>	*15:16:01:01-15:17:07, 15:67, 15:74, 15:95, 15:162, 15:168, 15:177, 15:196, 15:208, 15:216, 15:222, 15:230, 15:254, 15:268, 15:273, 15:356, 15:361-15:362, 15:396, 15:403, 15:408, 15:411, 15:423- 15:424, 15:446, 15:462, 15:500, 15:516, 15:523, 15:532, 15:550, 15:555, 15:575N, 15:602-15:603, 15:613, 15:619	
<b>20</b>	360 bp 505 bp	1070 bp	*15:105 *15:16:01:01-15:16:05, 15:34:01- 15:34:02, 15:62, 15:67, 15:85-15:86, 15:95, 15:137, 15:194, 15:222, 15:242:02, 15:254, 15:303, 15:362, 15:393, 15:407-15:408, 15:485-15:486,	*46:11, 46:18, 46:33, 46:53, 46:67



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00



101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Lot No.: <b>9N3</b>			Lot-specific information
			15:550, 15:552, 15:587, 15:599, 15:602, 15:613, 15:623
<b>21</b>	205 bp	1070 bp	*15:16:01:01-15:16:05, 15:67, 15:95, 15:222, 15:254, 15:362, 15:408, 15:550, 15:602, 15:613
	425 bp		*15:43
<b>22</b>	190 bp	<b>800 bp</b>	*07:20, 07:24, 07:60, 07:100, 07:131, 07:220, 07:223, 07:235, 07:358, 08:21, 08:25, 08:175, 13:03-13:04, 13:48, 13:62, 13:86, 13:120, 13:146, 13:164, 18:36, 18:56-18:58, 18:101, 18:164, 18:169, 27:153, 35:01:01:01-35:01:35, 35:01:37-35:01:49, 35:01:51-35:02:07, 35:02:09-35:03:05, 35:03:07-35:14:03, 35:16-35:30:01:02, 35:32:01-35:32:03, 35:34, 35:36-35:43:01, 35:43:03-35:59:02, 35:61:01-35:64:02, 35:67-35:72, 35:74-35:85, 35:89-35:92, 35:94-35:95, 35:97-35:130N, 35:132-35:156, 35:158-35:163, 35:165N-35:187, 35:189, 35:191-35:212, 35:214, 35:216N-35:229, 35:231-35:233, 35:235-35:260, 35:263-35:275, 35:278-35:321, 35:323-35:332, 35:334-35:340, 35:342, 35:344-35:349, 35:351-35:365, 35:367-35:374, 35:376-35:425, 35:427N-35:430N, 35:432-35:445, 35:447-35:459N, 35:462-35:467, 35:469, 35:472-35:479, 35:481-35:533, 35:535-35:544, 35:546, 35:548-35:550, 37:94, 38:30, 38:65, 39:32-39:33, 39:74, 40:05:01:01-40:05:02, 40:26, 40:28, 40:63, 40:71, 40:92, 40:174, 40:324, 40:343, 40:496, 41:17, 41:62, 44:10, 44:14, 44:17, 44:43:01-44:43:02, 44:45, 44:51, 44:62, 44:77, 44:82, 44:107, 44:123, 44:135, 44:184, 44:213, 44:230, 44:276, 44:339, 44:459, 45:09, 45:14, 46:01:01:01-46:01:35, 46:01:37-46:01:38, 46:02, 46:04-46:05, 46:07N-46:17, 46:19-46:20, 46:22-46:28, 46:31-46:50, 46:52-46:82, 46:84, 46:86-46:96, 48:02:01-48:02:03, 48:25, 49:04:01-49:04:02, 51:01:01:01-51:01:31, 51:01:33-51:01:38, 51:01:40-51:01:49, 51:01:51-51:01:58, 51:01:60-51:09:03, 51:11N-51:15, 51:19-51:20, 51:22-51:24:05, 51:26-51:30, 51:32-51:33, 51:35, 51:37-51:41N, 51:43-51:46, 51:48-51:80, 51:83-51:84, 51:86-51:92:02, 51:94-51:100,



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

			15:593, 15:595, 15:598-15:602, 15:604N-15:612, 15:614:01:01- 15:614:01:02, 15:616Q-15:618, 15:620- 15:624, 15:626, 15:628, 15:631-15:632	51:102-51:142, 51:145-51:152, 51:154-51:156, 51:158:01-51:171, 51:173Q-51:196, 51:198-51:215, 51:217-51:222, 51:224-51:226, 51:228-51:253, 51:255-51:260, 51:262-51:273N, 51:275-51:279, 51:281-51:294, 51:296-51:297, 51:299, 51:301-51:322, 51:324- 51:339, 51:341-51:351, 51:353- 51:358, 51:360-51:367, 52:01:01:01- 52:01:10, 52:01:12-52:01:20, 52:01:22-52:07:02, 52:09:01-52:25:02, 52:27-52:36, 52:38-52:62, 52:64- 52:66, 52:68-52:70, 52:72-52:83, 52:85-52:87, 52:89N-52:107, 53:01:01:01-53:01:06, 53:01:08- 53:01:16, 53:01:18-53:06, 53:08:01- 53:55, 53:57-53:61, 53:63-53:68, 54:03, 54:06, 54:33, 54:40, 55:08, 55:51, 56:01:01:01-56:01:12, 56:01:14-56:09, 56:11, 56:13-56:17, 56:20:01-56:22, 56:24-56:30, 56:33- 56:53, 56:55:01:02-56:59, 56:61- 56:65, 56:67-56:87, 57:01:01:01- 57:01:02, 57:01:04-57:03:05, 57:06- 57:12, 57:14:01-57:24, 57:27- 57:31:02, 57:33-57:40, 57:42, 57:44- 57:94, 57:96-57:149, 57:151-57:158, 58:01:01:01-58:01:25, 58:01:27- 58:01:29, 58:01:31-58:02:02, 58:04, 58:06-58:19, 58:21-58:26, 58:28:01- 58:29, 58:31N-58:34, 58:36, 58:38- 58:75, 58:77-58:83, 58:85, 58:87- 58:113, 58:115-58:133N, 58:135, 59:04, 59:12, 78:01:01:02-78:06, 78:09-78:10, 82:01:01:01-82:04, <b>C*03:81, C*03:175, C*03:199, C*03:245, C*03:317, C*03:388, C*15:15, C*15:195</b>
<b>23<sup>8</sup></b>	230 bp	<b>800 bp</b>	*15:19, 15:304N	*46:24
<b>24</b>	205 bp 305 bp	1070 bp	*15:26N *15:33, 15:72, 15:78:01:01-15:78:04, 15:107, 15:116, 15:141, 15:150, 15:188, 15:209N, 15:248, 15:287, 15:352, 15:421, 15:524, 15:614:01:01- 15:614:01:02	*46:06, 46:45
<b>25</b>	315 bp 385 bp	1070 bp	*15:46, 15:53, 15:106, 15:212  *15:28, 15:428	*40:26, 40:40, 40:516, 44:02:68, <b>C*16:85</b>
<b>26</b>	230 bp	1070 bp	*15:32:01-15:32:02, 15:299, 15:583	*35:433, 58:121, <b>C*03:178, C*03:474, C*07:186, C*07:242, C*07:265, C*07:748</b>



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

27 <sup>4</sup>	115 bp	1070 bp	*15:33, 15:248	*49:22, 51:126, 57:54, 57:96, <b>C*03:87:01-03:87:02, C*03:414,</b> <b>C*05:27, C*05:39, C*05:184,</b> <b>C*08:115, C*08:182</b>
	195 bp		*15:400N	
28	240 bp	1070 bp	*15:35:01:01-15:35:01:02, 15:141, 15:290, 15:381, 15:597	
	255 bp	1070 bp	*15:37-15:38:02, 15:185, 15:323, 15:335, 15:364, 15:368, 15:435, 15:610	*07:218, 07:220, 08:118, 14:01:12, 14:05-14:06:01, 14:08:02, 14:13, 14:53, 14:56, 14:96, 18:01:01:01- 18:01:05, 18:01:07-18:01:40, 18:01:42-18:01:49, 18:01:51, 18:03:01:01-18:07:03:02, 18:09, 18:12:01-18:15, 18:17N, 18:19-18:20, 18:23N-18:26, 18:28-18:34, 18:36- 18:44:01, 18:45-18:51, 18:53-18:55, 18:57:01-18:57:02, 18:59-18:100, 18:102-18:104, 18:106Q-18:109, 18:111-18:140, 18:142-18:148, 18:151-18:163, 18:166-18:167, 18:169, 18:172-18:178, 18:180- 18:188, 18:190-18:203, 18:205- 18:209, 18:211-18:222, 35:519, 39:32, 39:43, 39:48, 40:51, 40:113, 40:163, 40:174, 51:06:01:01-51:06:01:03, 51:06:03-51:06:04, 51:45, 51:62, 51:64, 51:135, 51:194, 51:293, 51:319, 51:341, 56:31, 67:06, <b>C*02:142</b>
30 <sup>6</sup>	320 bp	1070 bp	*15:40:01-15:40:02, 15:47:01-15:47:02, 15:49, 15:52, 15:114, 15:117, 15:124, 15:138, 15:238, 15:241, 15:389, 15:421, 15:519, 15:532	
	355 bp		*15:75, 15:312	*46:06, 46:25, 46:30
	405 bp		*15:375N	
31	320 bp	1070 bp	*15:44, 15:50, 15:69, 15:83:01:01- 15:83:01:02, 15:86, 15:93, 15:121, 15:186, 15:188, 15:199, 15:218Q, 15:224, 15:252, 15:265, 15:323, 15:348, 15:368, 15:449, 15:485, 15:494, 15:497, 15:566, 15:592	*46:03, 46:18, 46:21:01-46:21:02, 46:29, 46:83
	395 bp		*15:114, 15:153	
32	275 bp	1070 bp	*15:196	*46:19, 46:93
	350 bp		*15:190N	
	380 bp		*15:48, 15:108, 15:136, 15:235, 15:249	
33	200 bp	1070 bp	*15:118	*46:11, 46:18
	255 bp		*15:18:03, 15:42, 15:73:01:01- 15:73:01:02, 15:86, 15:224, 15:303, 15:485-15:486, 15:552	
	340 bp		*15:192, 15:281, 15:424	
34	160 bp	1070 bp	*15:51, 15:179:01-15:179:02, 15:199, 15:218Q, 15:518	*08:28, 08:35, 08:37, 08:89, 08:107, 08:291, 18:56, 18:113, 35:115, 35:260, 37:35, 37:56, 41:24, 41:30,



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

				41:51, 42:09, 42:32, 44:17, 44:230, 44:308, 45:09, 51:97, 53:22, 57:24, 57:119, <b>C*07:68, C*07:140:01-07:140:02, C*07:151, C*07:302, C*07:929</b>
<b>35</b>	165 bp	1070 bp	*15:30:01:01-15:30:01:03, 15:58, 15:73:01:01-15:73:01:02, 15:150, 15:303, 15:324, 15:453, 15:486, 15:541	*08:70, 08:281, 13:31, 13:41, 13:131, 13:145, 13:164, 35:44, 35:413, 39:36, 40:324, 40:466, 46:61, 46:74, 48:19, 51:61:01-51:61:02, 52:21:01-52:21:02, 52:97, 54:33, 54:40, 55:21, 56:43, <b>C*02:68, C*12:282</b>
<b>36<sup>6</sup></b>	360 bp 435 bp	<b>800 bp</b>	*15:82, 15:260 *15:36, 15:89:01-15:89:02, 15:115, 15:256, 15:339, 15:505, 44:02:68	<b>C*03:186:01, C*04:344, C*12:57:02 C*16:85</b>
<b>37</b>	170 bp	1070 bp	*15:47:01-15:47:02, 15:49, 15:65, 15:84, 15:99, 15:221, 15:237, 15:379, 15:519	*07:02:01:01-07:02:05, 07:02:07-07:02:17, 07:02:19-07:02:25, 07:02:27-07:02:45, 07:02:47-07:03, 07:05:01:01-07:13, 07:15-07:16, 07:18:01-07:18:02, 07:20-07:24, 07:27, 07:29-07:33:03, 07:35-07:42, 07:44N, 07:45 <sup>w</sup> , 07:46-07:47, 07:49N-07:51, 07:52 <sup>w</sup> , 07:53-07:54, 07:56:01-07:65, 07:67N-07:79, 07:81-07:95, 07:97-07:99, 07:101-07:114, 07:116-07:130, 07:132-07:145, 07:148-07:163, 07:165-07:171, 07:173-07:177, 07:179-07:196, 07:198-07:208, 07:210-07:222, 07:224, 07:227-07:234, 07:236-07:259, 07:261-07:283, 07:285N-07:334, 07:336-07:348, 07:350-07:358, 07:360Q-07:385, 07:387-07:406, 07:408-07:410, 07:412-07:419, 07:421-07:462, 08:20:01-08:20:02, 08:40, 08:79, 08:156, 13:18, 13:73, 13:128, 18:13, 18:21, 18:30, 35:08:01:01-35:08:15, 35:18, 35:45, 35:61:01-35:61:02, 35:66, 35:80, 35:99-35:100, 35:105, 35:142, 35:156, 35:158, 35:172, 35:174, 35:176, 35:187, 35:192, 35:206, 35:225, 35:229, 35:232, 35:262, 35:300-35:301, 35:328, 35:333Q, 35:337:01-35:338, 35:341-35:342, 35:346, 35:356, 35:386, 35:388, 35:411, 35:437, 35:444-35:445, 35:461N, 35:466, 35:481, 35:488, 35:493-35:494, 37:07, 39:08 <sup>w</sup> , 39:11 <sup>w</sup> , 39:33, 40:15-40:16:01:02, 40:23, 40:32, 40:98, 40:128, 40:161, 40:198, 40:496, 41:62, 46:03, 46:62, 48:05, 48:08, 51:05:01:01-51:05:01:02, 51:29, 51:54, 51:82, 51:217, 51:279, 52:24, 53:11, 53:16, 53:24, 53:55, 54:10, 54:20, 55:09, 55:37, 55:52,



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

				56:51, 56:63, 57:02:01:01-57:02:02, 57:12-57:13, 57:19, 57:28N, 57:30, 57:42, 57:63, 58:22, <b>C*01:90, C*01:101-01:102, C*01:113, C*01:116, C*04:108, C*05:132, C*05:215, C*05:238, C*07:850, C*14:92, C*15:08:01-15:08:02, C*15:143, C*15:148</b>
<b>38</b>	225 bp	1070 bp	*15:61, 15:70, 15:76, 15:101, 15:180 <sup>w</sup> , 15:189:01-15:189:02, 15:236, 15:255, 15:397 <sup>w</sup> , 15:553, 15:563, 15:579 <sup>w</sup> , 15:594, 15:603 <sup>w</sup> , 15:612	*07:29 <sup>w</sup> , 07:65, 07:72, 07:86, 07:352, 08:01:01:01 <sup>w</sup> -08:01:66 <sup>w</sup> , 08:04:01 <sup>w</sup> -08:05 <sup>w</sup> , 08:07 <sup>w</sup> -08:22 <sup>w</sup> , 08:24 <sup>w</sup> -08:53:02 <sup>w</sup> , 08:55 <sup>w</sup> -08:65 <sup>w</sup> , 08:67:01N <sup>w</sup> -08:71 <sup>w</sup> , 08:73 <sup>w</sup> -08:93 <sup>w</sup> , 08:95 <sup>w</sup> -08:109 <sup>w</sup> , 08:111 <sup>w</sup> -08:116 <sup>w</sup> , 08:118 <sup>w</sup> -08:125 <sup>w</sup> , 08:127 <sup>w</sup> -08:130 <sup>w</sup> , 08:132 <sup>w</sup> , 08:134 <sup>w</sup> -08:138 <sup>w</sup> , 08:140 <sup>w</sup> -08:150 <sup>w</sup> , 08:152 <sup>w</sup> -08:157 <sup>w</sup> , 08:160 <sup>w</sup> -08:189:02 <sup>w</sup> , 08:191 <sup>w</sup> -08:216 <sup>w</sup> , 08:218 <sup>w</sup> -08:225 <sup>w</sup> , 08:227 <sup>w</sup> -08:241 <sup>w</sup> , 08:243 <sup>w</sup> -08:254 <sup>w</sup> , 08:256 <sup>w</sup> -08:270Q <sup>w</sup> , 08:273 <sup>w</sup> -08:294 <sup>w</sup> , 08:296 <sup>w</sup> , 14:11, 14:28 <sup>w</sup> , 27:106 <sup>w</sup> , 35:29:01-35:29:03, 35:69, 35:76, 35:136, 35:186 <sup>w</sup> , 35:198, 35:229, 35:254, 35:294, 35:316, 35:472, 35:497, 39:04, 39:63, 40:43 <sup>w</sup> , 40:166 <sup>w</sup> , 40:513, 41:27 <sup>w</sup> , 41:47, 44:90, 44:277, 45:06 <sup>w</sup> , 46:01:01:01 <sup>w</sup> -46:01:01:08 <sup>w</sup> , 46:01:03 <sup>w</sup> -46:01:32 <sup>w</sup> , 46:01:34 <sup>w</sup> -46:01:39 <sup>w</sup> , 46:03 <sup>w</sup> -46:04 <sup>w</sup> , 46:06 <sup>w</sup> -46:34 <sup>w</sup> , 46:36 <sup>w</sup> -46:49 <sup>w</sup> , 46:51Q <sup>w</sup> -46:76 <sup>w</sup> , 46:78 <sup>w</sup> -46:96 <sup>w</sup> , 49:67 <sup>w</sup> , 50:52 <sup>w</sup> , 51:20 <sup>w</sup> , 51:208 <sup>w</sup> , 53:23 <sup>w</sup> , 54:01:01:01-54:01:03, 54:01:05-54:01:09, 54:03-54:11, 54:12 <sup>w</sup> , 54:13-54:22, 54:24-54:29, 54:31-54:38, 54:40-54:45, 55:01:01:01-55:01:07, 55:01:09-55:02:16, 55:03 <sup>w</sup> , 55:04-55:05, 55:07-55:09, 55:11, 55:12 <sup>w</sup> , 55:13-55:15, 55:16 <sup>w</sup> , 55:17, 55:19-55:24, 55:25 <sup>w</sup> , 55:26-55:30, 55:32-55:48, 55:49 <sup>w</sup> , 55:50-55:68, 55:69 <sup>w</sup> , 55:70-55:75, 55:77-55:81, 55:83N-55:89N, 55:91-55:102, 55:103 <sup>w</sup> , 55:104-55:120, 55:122-55:126, 56:01:01:01-56:01:08, 56:01:10-56:06, 56:08-56:20:02, 56:21 <sup>w</sup> , 56:22, 56:24-56:34, 56:36-56:40, 56:41 <sup>w</sup> , 56:43, 56:45-56:53, 56:55:01:02, 56:57-56:63, 56:65 <sup>w</sup> , 56:66, 56:68-56:83, 56:85-56:87, 78:01:01:02-78:01:02, 78:03, 78:07-78:08, 83:01, <b>C*07:441:01<sup>w</sup>-07:441:02<sup>w</sup>, C*16:86<sup>w</sup>, C*16:147<sup>w</sup> C*07:213, C*07:602</b>
<b>39</b>	315 bp 385 bp	<b>800 bp</b>	*15:60, 15:119 *15:95, 15:285, 15:378	



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

40 <sup>5</sup>	220 bp  425 bp	1070 bp	*15:71, 15:175, 15:381, 15:571  *15:13:01-15:13:03, 15:16:01:01-15:17:07, 15:23-15:24:02, 15:67, 15:95, 15:157, 15:162, 15:168, 15:177, 15:196, 15:208, 15:216, 15:222, 15:230, 15:254, 15:268, 15:273, 15:356, 15:361-15:362, 15:396, 15:403, 15:408, 15:411, 15:418, 15:423-15:424, 15:442, 15:446, 15:462, 15:500, 15:516, 15:523, 15:532, 15:550, 15:575N, 15:586, 15:602-15:603, 15:613, 15:619, 51:367	*27:195, 40:26, <b>C*03:504, C*06:77, C*07:714, C*07:724</b>
41	465 bp	1070 bp	*15:01:01:01-15:01:04, 15:01:06-15:08:02, 15:11:01-15:16:05, 15:18:01:01-15:19, 15:21:01:01-15:21:01:02, 15:23-15:29:01:02, 15:31:01:01-15:36, 15:38:01-15:40:02, 15:43-15:44, 15:46-15:47:02, 15:49-15:57, 15:60-15:62, 15:64:01-15:72, 15:74-15:76, 15:78:01:01-15:82, 15:84-15:85, 15:87-15:89:02, 15:91-15:98, 15:101-15:129, 15:131-15:132, 15:134-15:136, 15:138-15:149N, 15:151-15:161, 15:163-15:167, 15:169-15:176, 15:178-15:187, 15:189:01-15:195, 15:197:01-15:207, 15:209N-15:215, 15:217-15:223, 15:225-15:227, 15:231-15:232, 15:234-15:242:02, 15:244-15:247, 15:249-15:251:03, 15:254-15:268, 15:270-15:272N, 15:274-15:286, 15:288-15:302N, 15:304N-15:311, 15:314-15:322, 15:325-15:328, 15:330-15:333, 15:335-15:337, 15:340-15:341, 15:343-15:355, 15:357-15:360, 15:362-15:382, 15:384-15:395, 15:397-15:399, 15:401-15:402, 15:404-15:410, 15:412-15:415, 15:417-15:419, 15:421-15:422, 15:425-15:426, 15:428-15:434, 15:436-15:438, 15:440-15:444, 15:447-15:454N, 15:456-15:459, 15:461, 15:463N-15:484, 15:487N, 15:489-15:499, 15:501-15:502, 15:504-15:505, 15:507-15:515, 15:517-15:522, 15:524-15:529, 15:531, 15:533-15:540N, 15:542-15:545, 15:547-15:551, 15:554, 15:556-15:562N, 15:564-15:574, 15:576-15:577, 15:579-15:584N, 15:586-15:602, 15:604N-15:610, 15:612-15:618, 15:621-15:632	*35:43:01, 35:135, 35:185, 46:01:01:01-46:10, 46:12-46:17, 46:19-46:60, 46:62-46:69, 46:71-46:73, 46:75-46:80, 46:82-46:96, 51:220, 56:03
42	350 bp	1070 bp	*15:02:01:01-15:03:13, 15:05:01:01-15:06, 15:09:01-15:10:08, 15:13:01-15:13:03, 15:16:01:01-15:18:10, 15:21:01:01-15:21:01:02, 15:23, 15:25:01:01-15:25:04, 15:29:01:01-15:29:01:02, 15:31:01:01-15:31:01:03,	*46:06, 46:08, 46:11, 46:13:01-46:13:03, 46:18-46:19, 46:21:01-46:21:02, 46:25-46:26, 46:33, 46:43, 46:83, 46:93



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00



101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

			15:36-15:37, 15:39:01:01-15:40:02, 15:44, 15:48, 15:52, 15:55, 15:61-15:62, 15:64:01-15:64:02, 15:67, 15:69, 15:72-15:74, 15:80, 15:86, 15:88 <sup>w</sup> , 15:89:01-15:91, 15:93, 15:95, 15:98, 15:103, 15:106-15:108, 15:112, 15:114-15:115, 15:119, 15:121, 15:123-15:124, 15:127, 15:131-15:134, 15:136, 15:138-15:139, 15:151, 15:153, 15:155-15:156, 15:158, 15:161-15:162, 15:170, 15:173, 15:176 <sup>w</sup> , 15:177, 15:185-15:186, 15:188, 15:194-15:198, 15:200 <sup>w</sup> , 15:204, 15:208, 15:210, 15:213-15:214, 15:216, 15:219-15:220:04, 15:222-15:224, 15:226N, 15:229-15:230, 15:235, 15:238, 15:240, 15:242:01-15:243, 15:250 <sup>w</sup> , 15:252-15:255, 15:263, 15:265-15:266, 15:268, 15:271, 15:273-15:275:02, 15:281-15:283, 15:288-15:294N, 15:297, 15:301-15:303, 15:306-15:308, 15:310-15:311, 15:312 <sup>w</sup> , 15:313-15:314, 15:319, 15:323, 15:325, 15:328-15:330, 15:332, 15:335, 15:337-15:339, 15:341, 15:345, 15:348, 15:351, 15:354, 15:356-15:358, 15:360-15:362, 15:364, 15:366, 15:369, 15:374, 15:376, 15:378, 15:380N, 15:382, 15:384, 15:388-15:389, 15:393-15:397, 15:399, 15:402-15:404, 15:407-15:408, 15:411 <sup>w</sup> , 15:414, 15:418, 15:420-15:421, 15:423-15:427, 15:433-15:439, 15:444-15:449, 15:451, 15:454N-15:455, 15:458, 15:460, 15:462-15:463N, 15:468, 15:475, 15:485-15:487N, 15:491, 15:494-15:495, 15:497, 15:500, 15:502-15:506, 15:508-15:509, 15:511, 15:516-15:517, 15:523, 15:526-15:527, 15:530, 15:532, 15:537, 15:539, 15:543-15:544N, 15:546Q, 15:548, 15:550, 15:552-15:553, 15:555, 15:557, 15:560, 15:563-15:564, 15:566-15:567, 15:570-15:571, 15:573-15:575N, 15:577, 15:582, 15:584N, 15:587-15:589, 15:592, 15:594, 15:596N, 15:599, 15:602-15:603, 15:607, 15:610-15:617, 15:619-15:620, 15:623, 15:625-15:630	
	460 bp		*15:73:01:01-15:73:01:02, 15:86, 15:224, 15:303, 15:485-15:486, 15:552	*46:11, 46:18
<b>43</b>	525 bp	1070 bp	*15:04:01:01-15:04:04, 15:16:01:01-15:16:05, 15:67, 15:83:01:01-15:83:01:02, 15:95, 15:137, 15:155, 15:222, 15:254, 15:293, 15:303, 15:310, 15:362, 15:408, 15:485, 15:499, 15:517, 15:531, 15:550, 15:552, 15:602, 15:609, 15:613	*46:11, 46:18, 46:32:01-46:32:02



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Lot No.	Size	Length	Alleles
44	515 bp	1070 bp	*15:01:01:01-15:01:04, 15:01:06-15:01:13, 15:01:15-15:01:72, 15:01:74-15:01:75, 15:03:01:01-15:03:06, 15:03:08-15:03:13, 15:05:01:01-15:05:03, 15:07:01:01-15:11:02, 15:11:04-15:12:03, 15:14-15:15:01:02, 15:17:01:01-15:18:01:12, 15:18:03-15:19, 15:23-15:24:02, 15:26N <sup>w</sup> , 15:28-15:31:01:03, 15:33-15:35:01:02, 15:37-15:40:02, 15:43, 15:45-15:58, 15:60-15:61, 15:63-15:66, 15:68-15:76, 15:78:01:01-15:79N, 15:81-15:82, 15:87, 15:90-15:94N, 15:96-15:99, 15:101-15:105, 15:107-15:108, 15:111N, 15:113-15:120, 15:122-15:128, 15:131-15:136, 15:138, 15:140-15:143, 15:145-15:153, 15:156-15:169, 15:171-15:183, 15:185-15:193, 15:196-15:203, 15:205-15:212, 15:215-15:221, 15:224-15:227, 15:229-15:239, 15:241-15:242:01, 15:243-15:249, 15:251:01-15:253, 15:255-15:264, 15:266-15:270, 15:272N-15:282, 15:284-15:288, 15:290, 15:292, 15:294N-15:296, 15:298, 15:300, 15:304N-15:307, 15:309, 15:311-15:318, 15:320-15:324, 15:326, 15:329, 15:331-15:340, 15:343, 15:346-15:356, 15:359-15:361, 15:363:01-15:365, 15:367-15:373, 15:375N-15:377Q, 15:379-15:382, 15:384-15:392, 15:396-15:397, 15:400N-15:401, 15:403, 15:405-15:406, 15:409-15:417, 15:419, 15:421-15:424, 15:426-15:436, 15:439-15:453, 15:455-15:457, 15:459, 15:461-15:462, 15:464-15:467, 15:469, 15:471-15:484, 15:486-15:490, 15:492-15:494, 15:496N-15:498, 15:500-15:504, 15:506-15:509, 15:511-15:516, 15:518-15:530, 15:532-15:533, 15:535-15:536, 15:538-15:542, 15:545-15:549N, 15:551, 15:553-15:556, 15:558-15:563, 15:565, 15:568, 15:570-15:573, 15:575N-15:582, 15:585-15:586, 15:588, 15:590-15:591, 15:593, 15:595, 15:597-15:598, 15:600-15:601, 15:603-15:608, 15:610-15:612, 15:614:01:01-15:614:01:02, 15:616Q-15:622, 15:624, 15:626, 15:628, 15:631-15:632
45	475 bp	1070 bp	*15:01:01:01-15:01:04, 15:01:06-15:01:75, 15:03:01:01-15:05:03, 15:07:01:01-15:12:03, 15:14-15:16:05, 15:18:01:01-15:19, 15:23-15:24:02, 15:26N-15:30:01:03, 15:32:01-15:35:01:02, 15:37-15:40:02, 15:43, 15:45-15:54, 15:56-15:58, 15:60-15:76,



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

**Lot-specific information**

			15:78:01:01-15:87, 15:90-15:99, 15:101-15:105, 15:107-15:111N, 15:113-15:120, 15:122-15:127, 15:129, 15:131-15:136, 15:138, 15:140-15:143, 15:145-15:155, 15:157-15:161, 15:163-15:167, 15:169, 15:171-15:176, 15:178-15:195, 15:197:01-15:203, 15:205-15:206, 15:209N-15:210, 15:212, 15:215, 15:217-15:220:02, 15:220:04-15:227, 15:229, 15:231-15:232, 15:234-15:239, 15:241-15:249, 15:251:01-15:264, 15:266-15:270, 15:272N, 15:274-15:282, 15:284-15:288, 15:290, 15:292-15:296, 15:298-15:300, 15:303-15:307, 15:309-15:318, 15:320-15:324, 15:326-15:327, 15:329, 15:331-15:338, 15:340, 15:343-15:344, 15:346-15:348, 15:350-15:355, 15:359, 15:361-15:365, 15:367-15:373, 15:375N-15:377Q, 15:379-15:382, 15:385-15:393, 15:397-15:398, 15:401-15:402, 15:406-15:410, 15:412-15:417, 15:419, 15:421-15:422, 15:426-15:436, 15:439-15:445, 15:447-15:453, 15:455-15:457, 15:459-15:461, 15:464-15:467, 15:469-15:487N, 15:489-15:490, 15:492-15:494, 15:496N-15:499, 15:501-15:504, 15:506-15:515, 15:517-15:522, 15:524-15:531, 15:533-15:536, 15:538-15:542, 15:545, 15:547-15:552, 15:554, 15:556, 15:558-15:563, 15:565, 15:568, 15:570-15:573, 15:576, 15:579-15:583, 15:585-15:588, 15:590-15:591, 15:593, 15:595, 15:598-15:602, 15:604N-15:612, 15:614:01:01-15:614:01:02, 15:616Q-15:618, 15:620-15:624, 15:626, 15:628, 15:631-15:632
46	360 bp	800 bp	*15:01:01:01-15:01:04, 15:01:06-15:04:04, 15:06-15:19, 15:21:01:01-15:21:01:02, 15:23-15:30:01:03, 15:32:01-15:40:02, 15:43-15:47:02, 15:49-15:50, 15:53-15:54, 15:56-15:58, 15:60-15:74, 15:76-15:82, 15:85, 15:87, 15:89:01-15:90, 15:92-15:99, 15:101-15:104, 15:106, 15:108-15:110, 15:112-15:113, 15:115-15:122, 15:125:01-15:129, 15:131-15:135, 15:137-15:144, 15:146-15:150, 15:152-15:154, 15:156-15:161, 15:163-15:175, 15:177-15:178, 15:180-15:184, 15:187, 15:189:01-15:199, 15:201-15:217, 15:219-15:221, 15:223, 15:225-15:227, 15:229-15:234, 15:236, 15:238-15:249, 15:251:01-15:274, 15:276-15:282, 15:284-15:311, 15:313-15:331, 15:333-15:347, 15:349:01-15:382, 15:384-15:392,
			*35:43:01, 35:135, 35:185, 46:01:01:01-46:05, 46:07N-46:08, 46:10, 46:12, 46:14-46:17, 46:20, 46:22-46:24, 46:26-46:32:02, 46:34-46:42, 46:44-46:96, 51:220, 56:03



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Lot No.: <b>9N3</b>		Lot-specific information	
			15:394-15:395, 15:397-15:406, 15:408-15:410, 15:412-15:414, 15:416-15:420, 15:422-15:448, 15:450-15:484, 15:486-15:498, 15:500-15:506, 15:508-15:517, 15:519-15:538, 15:540N-15:551, 15:553-15:576, 15:579-15:586, 15:588-15:598, 15:600-15:622, 15:624-15:627, 15:629-15:632
<b>47</b>	320 bp      1070 bp	*15:01:01:01-15:01:04, 15:01:06-15:01:30, 15:01:32-15:18:09, 15:19, 15:21:01:01-15:21:01:02, 15:23-15:27:03, 15:28-15:39:02, 15:43, 15:45-15:46, 15:48, 15:51, 15:53-15:58, 15:60-15:68, 15:70-15:82, 15:84-15:85, 15:87-15:92, 15:94N-15:99, 15:101-15:113, 15:115-15:116, 15:118-15:120, 15:122-15:123, 15:125:01-15:129, 15:131-15:137, 15:139-15:185, 15:187, 15:189:01-15:198, 15:200-15:217, 15:219-15:223, 15:225-15:227, 15:229-15:237, 15:239-15:240, 15:242:01-15:251:03, 15:253-15:264, 15:266-15:322, 15:324-15:340, 15:342-15:347, 15:349:01-15:367, 15:369-15:382, 15:384-15:388, 15:390-15:420, 15:422-15:448, 15:450-15:483N, 15:486-15:493, 15:495, 15:498-15:518, 15:520Q-15:531, 15:533-15:565, 15:567-15:579, 15:581-15:591, 15:593-15:632	*35:43:01, 35:135, 35:185, 46:01:01:01-46:02, 46:04-46:05, 46:07N-46:17, 46:19-46:20, 46:22-46:28, 46:31-46:82, 46:84, 46:86-46:96, 51:220, 56:03
<b>48</b>	420 bp      1070 bp	*15:01:01:01-15:01:04, 15:01:06-15:01:16, 15:01:17 <sup>w</sup> , 15:01:18-15:19, 15:21:01:01-15:21:01:02, 15:23-15:32:02, 15:34:01-15:40:02, 15:43-15:58, 15:60-15:71, 15:73:01:01-15:77, 15:79N-15:99, 15:101-15:106, 15:108-15:115, 15:117-15:129, 15:131-15:140, 15:142-15:149N, 15:151-15:187, 15:189:01-15:227, 15:229-15:247, 15:249-15:286, 15:288-15:294N, 15:296-15:351, 15:353-15:382, 15:384-15:420, 15:422-15:523, 15:525-15:613, 15:615-15:632	*35:43:01, 35:135, 35:185, 46:01:01:01-46:05, 46:07N-46:44, 46:46-46:53, 46:55N-46:57, 46:59-46:96, 51:220, 56:03
<b>49</b>	135 bp      1070 bp	*15:57, 15:135	*13:39, 13:67
<b>50<sup>4</sup></b>	85 bp      1070 bp	*15:67, 15:343	*35:110, 44:497, 58:77, <b>A*02:598, A*02:695, A*68:56:01-68:56:02, A*69:05</b>
	185 bp	*15:206	
<b>51</b>	135 bp      1070 bp	*15:98, 15:109, 15:163	*55:104
	175 bp	*15:277-15:278	*35:122, 40:339, 56:29
	200 bp	*15:246N	
<b>52</b>	200 bp <b>800 bp</b>	*15:104, 15:307, 15:321Q, 15:560, 15:591	*35:364, 35:379, 35:462, 39:187, 42:31, 51:142, 52:80, 57:116
	345 bp	*15:92, 15:213	



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

<b>53</b>	210 bp	<b>800 bp</b>	*15:96	*35:537, <b>C*03:175, C*03:199, C*03:245</b>
<b>54</b>	250 bp 410 bp	<b>800 bp</b>	*15:187 *15:97	<b>C*12:36</b>
<b>55<sup>6</sup></b>	175 bp	1070 bp	*15:214	*07:120, 14:61, 18:81, 35:250, 37:93, 39:145, 39:158, 40:150, 40:427, 44:311, 48:45, 51:165, 55:108, 57:29
	210 bp 255 bp		*15:321Q *15:102, 15:284	*35:474, 37:71, 39:179, 44:278, 51:30, 58:105, 73:01:01:01-73:03
<b>56<sup>4</sup></b>	70 bp 260 bp	1070 bp	*15:103 *15:227, 15:630	*07:329, 13:151, 18:183, 27:69, 27:192, 37:23, 40:213, 40:485, 42:28, 44:338
<b>57</b>	340 bp 480 bp	1070 bp	*15:111N, 15:300 *15:369	
<b>58</b>	175 bp	1070 bp	*15:113, 15:319	*44:500, 52:17
<b>59<sup>5</sup></b>	230 bp 370 bp 420 bp	<b>800 bp</b>	*15:191, 15:234 *15:198, 15:270 *15:94N, 15:294N	<b>C*06:33</b> *35:161
<b>60</b>	160 bp	<b>800 bp</b>	*15:20, 15:228, 15:271, 15:305, 15:435, 15:599	*27:197, 35:01:01:01-35:01:27, 35:01:29-35:01:46, 35:01:48-35:30:01:02, 35:32:01-35:32:02, 35:33-35:34, 35:36-35:42:02, 35:45, 35:47-35:56, 35:58-35:59:02, 35:61:01-35:72, 35:74-35:78, 35:80-35:86, 35:88-35:134N, 35:136-35:184, 35:186-35:208:01, 35:209-35:278, 35:280-35:358, 35:360-35:466, 35:468-35:470, 35:472-35:474, 35:477-35:482, 35:484:01-35:533, 35:535-35:544, 35:546-35:548, 35:550, 37:80, 48:02:01-48:02:03, 49:66, 51:01:01:01-51:01:55, 51:01:57-51:24:05, 51:26-51:41N, 51:43-51:46, 51:48-51:156, 51:158:01-51:163, 51:165-51:219, 51:221-51:236, 51:238-51:294, 51:296-51:299, 51:301-51:306N, 51:308-51:358, 51:360-51:367, 52:01:01:01-52:01:50, 52:02:01-52:06:03, 52:08-52:107, 53:01:01:01-53:01:27, 53:02-53:58, 53:60-53:68, 56:05:01-56:05:02, 56:21, 56:36, 58:01:01:01-58:01:21, 58:01:23-58:02:02, 58:04-58:10N, 58:12-58:19, 58:21-58:29, 58:31N-58:104, 58:107-58:135, 67:05, 78:01:01:02-78:10, 81:03
<b>61</b>	160 bp 205 bp	1070 bp	*15:175 *15:125:01	*40:331 *13:124, 14:73, 37:85, 40:342, 40:470, 44:22, 44:105, 49:24, <b>C*12:301</b>
<b>62<sup>4,5</sup></b>	105 bp	1070 bp	*15:126	*07:175



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

<b>63</b>	175 bp 280 bp	1070 bp	*15:127 *15:315	*46:77
<b>64<sup>4</sup></b>	90 bp 135 bp 240 bp 365 bp	<b>800 bp</b>	*15:302N *15:270 *15:301 *15:122	*08:246 <b>C*12:318, C*14:134</b> <b>C*03:48, C*05:126, C*06:85,</b> <b>C*07:540</b>
<b>65</b>	405 bp 470 bp 520 bp	1070 bp	*15:375N *15:232 *15:129, 15:342, 15:395, 15:629	*46:64
<b>66</b>	435 bp	1070 bp	*15:02:01:01-15:02:12, 15:13:01- 15:13:03, 15:20-15:21:01:02, 15:25:01:01-15:25:04, 15:36, 15:44, 15:77, 15:85, 15:88-15:89:02, 15:118, 15:121, 15:139, 15:144, 15:154, 15:194, 15:204, 15:213-15:214, 15:223, 15:240, 15:250, 15:265, 15:271, 15:283, 15:289, 15:291, 15:297, 15:301-15:302N, 15:319, 15:325, 15:328, 15:330, 15:341, 15:345, 15:357-15:358, 15:366, 15:374, 15:378, 15:393-15:394, 15:399, 15:402, 15:404, 15:407, 15:418, 15:420, 15:425, 15:437-15:438, 15:454N, 15:458, 15:460, 15:463N, 15:468, 15:491, 15:495, 15:505, 15:537, 15:543- 15:544N, 15:557, 15:564, 15:566- 15:567, 15:569, 15:574, 15:584N, 15:587, 15:589, 15:592, 15:594, 15:596N, 15:599, 15:615, 15:623, 15:625, 15:627, 15:630	*13:01:01:01-13:01:19, 13:06-13:07N, 13:12:01-13:13:02, 13:17, 13:20- 13:23, 13:25-13:26:02, 13:28-13:29, 13:36, 13:39, 13:43, 13:50-13:52, 13:57, 13:60-13:61, 13:63N, 13:73, 13:77-13:78, 13:80, 13:83, 13:86-13:87, 13:90, 13:92, 13:95, 13:106-13:107, 13:109-13:110, 13:122, 13:129, 13:135, 13:138, 13:141-13:142, 13:144, 13:146, 13:148, 13:161N-13:163, 13:168, 13:170-13:171, 13:173, 35:46, 35:207, 35:311, 40:137, 44:08, 44:57, 44:60, 46:33, 46:67, 57:01:01:01-57:01:33, 57:01:35-57:10, 57:12-57:15, 57:17- 57:33, 57:34 <sup>w</sup> , 57:35-57:44, 57:46- 57:50, 57:52-57:66, 57:68, 57:70- 57:81, 57:84-57:97, 57:99-57:117, 57:119, 57:121-57:158, 58:36
<b>67</b>	265 bp	<b>800 bp</b>	*15:53, 15:183, 15:212, 15:336, 15:345, 15:511, 15:559	*27:195, 40:26, 40:40, 40:516, 44:02:68, 46:10, <b>C*02:167, C*03:504,</b> <b>C*04:459, C*05:205, C*06:284,</b> <b>C*07:828, C*16:85</b> <b>C*07:02:92</b>
	300 bp		*15:132	
<b>68<sup>5,6</sup></b>	215 bp 380 bp	1070 bp	*15:134 *15:247	*44:284, <b>C*03:490, C*03:548,</b> <b>C*05:03</b>
<b>69</b>	130 bp	1070 bp	*15:57	
<b>70<sup>4</sup></b>	90 bp 185 bp	1070 bp	*15:208 *15:138, 15:230, 15:241, 15:297	*51:252 *07:68:01-07:68:03, 07:214, 07:237, 07:262:01-07:262:02, 07:424, 18:35, 18:110, 35:66, 40:77, 40:87:01- 40:87:02, 40:121, 40:158, 40:222, 40:237, 40:368, 40:422, 44:150, 46:87, 48:12, 48:14, 48:26, 48:29
<b>71</b>	290 bp 315 bp 400 bp	1070 bp	*15:53, 15:212, 15:336, 15:347, 15:559, 15:588 *15:205 *15:139	*27:195, 40:26, 40:40, 40:516, 44:02:68, <b>C*01:124, C*16:85</b>
<b>72<sup>4</sup></b>	110 bp 200 bp 295 bp	1070 bp	*15:226N *15:380N *15:140	*35:216N, 38:165N, 39:87N <b>C*15:199</b> *35:543, 51:166



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00



101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

390 bp		*15:201	
73	155 bp	1070 bp	*15:09:01-15:09:02, 15:30:01:01 <sup>w</sup> -15:30:01:03 <sup>w</sup> , 15:42, 15:58 <sup>w</sup> , 15:73:01:01 <sup>w</sup> -15:73:01:02 <sup>w</sup> , 15:150 <sup>w</sup> , 15:229, 15:243, 15:252, 15:303 <sup>w</sup> , 15:324 <sup>w</sup> , 15:329, 15:361, 15:435, 15:453 <sup>w</sup> , 15:460, 15:486 <sup>w</sup> , 15:541 <sup>w</sup>  *07:05:01:01-07:06:05, 07:32, 07:34, 07:40, 07:53, 07:69, 07:78, 07:80, 07:90, 07:97, 07:105, 07:112, 07:123, 07:137-07:138, 07:140, 07:176, 07:182N, 07:201N, 07:206-07:207, 07:210, 07:213-07:214, 07:222, 07:249, 07:258, 07:262:01-07:262:02, 07:264, 07:269-07:270, 07:278, 07:283, 07:287, 07:293, 07:304, 07:317, 07:324, 07:327, 07:333, 07:340, 07:352-07:353, 07:356-07:358, 07:368, 07:378, 07:387, 07:389, 07:395, 07:399, 07:426Q, 07:434, 07:443, 08:20:01-08:20:02, 08:79, 08:281 <sup>w</sup> , 13:16, 13:20, 13:31 <sup>w</sup> , 13:48, 13:62, 13:128, 13:131 <sup>w</sup> , 13:145 <sup>w</sup> , 14:13, 14:53, 14:96, 27:20, 27:24, 27:153, 27:168, 35:44 <sup>w</sup> , 35:384, 35:413 <sup>w</sup> , 38:10, 38:32, 38:98, 39:35, 39:36 <sup>w</sup> , 39:107, 40:05:01:01-40:05:02, 40:15-40:16:01:02, 40:23, 40:26, 40:28, 40:51, 40:95, 40:148, 40:158, 40:161, 40:174, 40:183, 40:198, 40:309, 40:355, 40:466 <sup>w</sup> , 40:496, 42:19, 44:459, 46:61 <sup>w</sup> , 46:74 <sup>w</sup> , 48:05, 48:15, 51:01:01:01-51:01:18, 51:01:19 <sup>w</sup> , 51:01:20-51:01:30, 51:01:32-51:01:49, 51:01:51-51:02:02, 51:02:04-51:04:02, 51:06:01:01-51:07:02, 51:11N-51:14, 51:16, 51:21-51:24:05, 51:26-51:30, 51:32-51:35, 51:38-51:39, 51:41N, 51:43, 51:46, 51:48-51:53, 51:55-51:60, 51:61:01 <sup>w</sup> -51:61:02 <sup>w</sup> , 51:62-51:71, 51:74-51:80, 51:82-51:84, 51:86, 51:88-51:89, 51:95-51:96, 51:98N-51:107, 51:109-51:114, 51:116-51:121, 51:123-51:134, 51:136-51:138, 51:140, 51:142-51:145, 51:147, 51:149N-51:152, 51:154-51:156, 51:158:01-51:171, 51:173Q-51:180, 51:182-51:193:02, 51:195-51:196, 51:198-51:205, 51:206 <sup>w</sup> , 51:207-51:210, 51:212-51:215, 51:218-51:219, 51:221-51:222, 51:224-51:226, 51:228-51:253, 51:255-51:258, 51:260, 51:262, 51:264N-51:273N, 51:277-51:279, 51:282-51:297, 51:299-51:336, 51:339, 51:341, 51:343-51:353, 51:355-51:358, 51:360-51:361N, 51:363-51:367, 52:01:01:01-52:01:10, 52:01:12-52:01:38, 52:01:39 <sup>w</sup> ,



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

				52:01:40-52:02:02, 52:04-52:09:02, 52:11:01-52:11:02, 52:13-52:18, 52:20, 52:21:01 <sup>w</sup> -52:21:02 <sup>w</sup> , 52:22-52:25:02, 52:27-52:43, 52:44 <sup>w</sup> , 52:45-52:56, 52:57 <sup>w</sup> , 52:58-52:62, 52:64-52:70, 52:72-52:73, 52:76-52:87, 52:89N-52:96N, 52:97 <sup>w</sup> , 52:98-52:107, 54:20, 54:33 <sup>w</sup> , 55:01:01:01-55:01:29, 55:03, 55:05, 55:09, 55:11, 55:15, 55:17, 55:21 <sup>w</sup> , 55:24-55:25, 55:28:01-55:29, 55:31, 55:33, 55:36, 55:38, 55:40, 55:44-55:45, 55:52-55:55N, 55:59-55:60, 55:64, 55:66, 55:73-55:76, 55:78-55:79, 55:84-55:85, 55:87, 55:90-55:95, 55:97N-55:106, 55:108-55:109, 55:111, 55:113-55:116, 55:118N-55:119, 55:121-55:122, 55:124-55:126, 56:05:01-56:06, 56:21, 56:25, 56:37, 56:66, 57:57, 57:63, 58:08:01-58:08:02, 59:12, 78:01:01:02-78:03, 78:05-78:07, 78:09, <b>C*01:90, C*01:116, C*02:68<sup>w</sup>, C*03:317, C*05:238, C*12:282<sup>w</sup>, C*14:92, C*15:24, C*15:128</b>
<b>74<sup>4</sup></b>	75 bp	<b>800 bp</b>	*15:145, 15:176, 15:411	*35:237, 35:352, 51:228, 52:28, 53:68, <b>C*03:420</b>
	230 bp		*15:262:01N	
<b>75</b>	280 bp 315 bp	1070 bp	*15:146 *15:367, 15:441	*51:48, <b>C*02:83, C*05:224, C*06:327, C*08:24, C*12:323, C*16:90, C*16:180</b>
	390 bp		*15:201	
<b>76</b>	475 bp	1070 bp	*15:02:01:01-15:02:12, 15:06, 15:13:01-15:13:03, 15:17:01:01-15:17:07, 15:21:01:01-15:21:01:02, 15:25:01:01-15:25:04, 15:31:01:01-15:31:01:03, 15:36, 15:44, 15:55, 15:77, 15:88-15:89:02, 15:106, 15:112, 15:121, 15:128, 15:137, 15:139, 15:144, 15:156, 15:162, 15:168, 15:170, 15:177, 15:196, 15:204, 15:208, 15:213-15:214, 15:216, 15:230, 15:233, 15:240, 15:250, 15:265, 15:271, 15:273, 15:283, 15:289, 15:291, 15:297, 15:301-15:302N, 15:308, 15:319, 15:325, 15:328, 15:330, 15:339, 15:341-15:342, 15:345, 15:356-15:358, 15:360, 15:366, 15:374, 15:378, 15:384, 15:394-15:396, 15:399, 15:403-15:405, 15:411, 15:418, 15:420, 15:423-15:425, 15:437-15:438, 15:446, 15:454N, 15:458, 15:462-15:463N, 15:468, 15:488, 15:491, 15:495, 15:500, 15:505, 15:516, 15:523, 15:532, 15:537, 15:543-15:544N, 15:546Q, 15:553, 15:555,	



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Lot No.: <b>9N3</b>		Lot-specific information	
			15:557, 15:564, 15:566-15:567, 15:569, 15:574-15:575N, 15:578, 15:584N, 15:589, 15:592, 15:594, 15:596N, 15:603, 15:613, 15:615, 15:619, 15:625, 15:627, 15:629-15:630
<b>77<sup>6,8</sup></b>	185 bp 330 bp	1070 bp	*15:174 *15:123, 15:220:01:01-15:220:04, 15:388, 15:475, 15:517, 15:539, 15:560, 15:571, 15:610
			*27:179, 35:549, 44:312, 51:299
<b>78<sup>4</sup></b>	110 bp	1070 bp	*15:142, 15:429
	385 bp 475 bp		*07:29, 07:186, 07:383, 08:01:11, 08:56:01, 08:133, 08:176, 08:180, 13:93, 35:218, 35:256, 37:62, 51:68, 51:176, 52:77, 57:49, <b>C*06:02:93,</b> <b>C*07:02:30</b> *46:42 *46:64
<b>79</b>	215 bp 365 bp 420 bp	<b>800 bp</b>	*15:182N *15:282 *15:148, 15:330
			<b>C*03:84, C*03:281, C*07:275</b>
<b>80<sup>4,5</sup></b>	85 bp 200 bp 225 bp 340 bp	1070 bp	*15:149N *15:380N *15:263 *15:320
			<b>C*15:199</b>
<b>81<sup>6</sup></b>	395 bp	1070 bp	*15:11:01-15:11:07, 15:143, 15:148- 15:149N, 15:152, 15:209N, 15:215, 15:284, 15:303, 15:305, 15:350, 15:367, 15:486, 15:513
<b>82<sup>4,5</sup></b>	80 bp 200 bp 245 bp	1070 bp	*15:81 *15:246N *15:277, 15:430
			*53:35, 58:47 *35:222, 35:525, 40:76, <b>C*05:30,</b> <b>C*06:125, C*16:144</b>
<b>83<sup>6</sup></b>	255 bp	1070 bp	*15:159, 15:260, 15:491
			*35:302, 35:391, 35:437, 35:539, 40:79, 41:14, 46:52
<b>84</b>	155 bp 195 bp 235 bp	1070 bp	*15:167 *15:211, 15:400N *15:197:01, 15:215
			*35:408, 44:496 <b>C*03:168</b> *35:117
<b>85<sup>5</sup></b>	340 bp 395 bp 420 bp	1070 bp	*15:157, 15:500 *15:76, 15:101, 15:255, 15:509 *15:164
			<b>C*03:542, C*07:335, C*14:62</b>
<b>86</b>	230 bp 260 bp 400 bp	1070 bp	*15:166 *15:272N *15:193
<b>87<sup>4</sup></b>	85 bp	1070 bp	*15:71, 15:175, 15:204, 15:225, 15:344, 15:381
	295 bp		*18:29, 18:98:01-18:98:02, 27:214, 35:50, 35:231, 35:280, 35:323, 37:22:01-37:22:03, 40:248, 40:282, 40:351, 40:364, 41:12, 41:36, 42:27, 46:14, 49:03, 49:48, 51:151, 52:51, 54:02, 55:16, 56:35, 57:39, 57:73, 58:41, <b>C*03:278, C*16:86</b>
<b>88</b>	240 bp 450 bp	<b>800 bp</b>	*15:169 *15:171 *15:158, 15:240, 15:377Q
			<b>C*07:756, C*14:67</b> <b>C*05:80, C*12:308, C*15:173</b>



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Lot No.:	Lot-specific information			
<b>89</b>	180 bp 240 bp	1070 bp	*15:160:01:01-15:160:01:02 *15:94N, 15:294N, 15:377Q	*08:72N
<b>90<sup>4</sup></b>	95 bp	1070 bp	*15:202, 15:239, 15:376	*07:400, 13:58, 18:12:01-18:12:02, 18:195, 35:10, 35:13, 35:16, 35:28:01:01-35:28:01:03, 35:69, 35:80, 35:226, 35:270, 35:318, 35:477, 35:534, 35:541, 37:01:01:01- 37:01:05, 37:01:07-37:05, 37:07, 37:09-37:27, 37:29-37:59, 37:62- 37:66, 37:68-37:81, 37:83-37:104, 40:185, 40:209, 40:308, 40:350, 40:365, 44:83, 44:134, 44:445, 49:03, 51:310, 52:01:01:01-52:01:51, 52:03- 52:15, 52:17, 52:19-52:31:02, 52:33-52:72, 52:74-52:107, 53:17:01- 53:17:02, 53:28, 53:38, 78:05-78:06 *18:63, 39:90, 44:486, 50:11, <b>A*01:201, A*02:695, A*24:343, A*24:562, A*25:66, A*26:200, A*32:158, A*68:56:02, A*69:05</b>
	195 bp		*15:173, 15:477	
<b>91<sup>6,7</sup></b>	135 bp 325 bp	1070 bp	*15:184, 15:203 *15:170, 15:356	*18:109, 38:62
<b>92<sup>4</sup></b>	95 bp 155 bp	1070 bp	*15:266, 15:332 *15:172, 15:328	*13:37, 38:49, 51:75 *50:78
<b>93<sup>9</sup></b>	255 bp 295 bp  385 bp	1070 bp	*15:258N, 15:304N *15:53, 15:177, 15:212, 15:336, 15:347, 15:559, 15:588 *15:120	*27:195, 40:26, 40:40, 40:516, 44:02:68, <b>C*01:124, C*16:85</b>
<b>94</b>	260 bp 285 bp 325 bp	1070 bp	*15:272N *15:123 *15:178	
<b>95<sup>5,6</sup></b>	160 bp 340 bp 395 bp	1070 bp	*15:358 *15:181N, 15:584N *15:40:01-15:40:02, 15:47:01-15:47:02, 15:49, 15:52, 15:114, 15:117, 15:124, 15:138, 15:238, 15:241, 15:389, 15:421, 15:519, 15:532	*46:06, 46:25, 46:30
<b>96<sup>10</sup></b>	-	-	<b>Negative Control</b>	

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-B\*15 SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings. Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

**Lot No.: 9N3**

**Lot-specific information**

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA Class I alleles 1st and/or 4th exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

<sup>4</sup>HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

<sup>5</sup>Primer mixes 40, 59, 62, 68, 80, 82, 85 and 95 have a tendency to giving rise to primer oligomer formation.

<sup>6</sup>Primer mixes 2, 5, 15, 30, 36, 55, 68, 77, 81, 83 and 95 may have tendencies of unspecific amplifications.

<sup>7</sup>Primer mix 91 may give rise to a long unspecific amplification product of approximately 800 bp. This should be disregarded when interpreting the B\*15 typings.

<sup>8</sup>Primer mixes 23 and 77 may give rise to a lower yield of HLA-specific PCR product than the other HLA-B\*15 resolution primer mixes.

<sup>9</sup>In primer mixes 1 and 93 the positive control band may be weaker than for other HLA-B\*15 primer mixes.

<sup>10</sup>Primer mix 96 contains a negative control, which will amplify the majority of the HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

Abbreviations

'w', might be weakly amplified.



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information  
**PRIMER SPECIFICATION**

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec. PCR product	400	290	120	180	385	525	330	105	365	300	140	400
				390						515		
Length of int. pos. control <sup>1</sup>	<b>800</b>	1070	1070	<b>800</b>	1070	1070	1070	1070	1070	1070	<b>800</b>	<b>800</b>
5'-primer(s) <sup>2</sup>	45 5'-ggA 3'	45 5'-ggA 3'	463 5'-TgA 3'	45 5'-ggA 3'	45 5'-ggA 3'	355 5'-TCA 3'	45 5'-ggA 3'	357 5'-Tgg 3'	2 <sup>nd</sup> I 5'-CAA 3'	360 5'-CAC 3'	363 5'-AgC 3'	45 5'-ggA 3'
										368 5'-gTT 3'		
										583 5'-gAC 3'		
3'-primer(s) <sup>3</sup>	272 5'-Tgg 3'	165 5'-Tgg 3'	538 5'-CCA 3'	1 <sup>st</sup> I 5'-gAC 3'	259 5'-gTT 3'	3 <sup>rd</sup> I 5'-ATC 3'	206 5'-CCT 3'	419 5'-Cgg 3'	527 5'-CCA 3'	3 <sup>rd</sup> I 5'-ATC 3'	463 5'-gCT 3'	272 5'-TgA 3'
	283 5'-Tgg 3'		545 5'-AgA 3'	267 5'-ATg 3'				419 5'-CgA 3'	527 5'-CCA 3'			287 5'-TCC 3'
Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec. PCR product	395	465	105	120	435	195	395	360	205	190	230	205
	435	515		190				505	425			305
Length of int. pos. control <sup>1</sup>	<b>800</b>	1070	1070	1070	1070	1070	<b>800</b>	1070	1070	<b>800</b>	<b>800</b>	1070
5'-primer(s) <sup>2</sup>	45 5'-ggA 3'	368 5'-gTg 3'	369 5'-TAC 3'	419 5'-gTC 3'	45 5'-ggA 3'	419 5'-gTC 3'	45 5'-ggA 3'	379 5'-ACC 3'	45 5'-ggA 3'	409 5'-ggC 3'	821 5'-gCT 3'	2 <sup>nd</sup> I 5'-CAA 3'
		419 5'-gTA 3'						523 5'-CCT 3'		410 5'-CCA 3'		
3'-primer(s) <sup>3</sup>	272 5'-TgC 3'	3 <sup>rd</sup> I 5'-ATC 3'	435 5'-TCT 3'	499 5'-ggA 3'	309 5'-ATC 3'	572 5'-gCg 3'	266 5'-TCC 3'	3 <sup>rd</sup> I 5'-ATC 3'	83 5'-TgA 3'	559 5'-CAg 3'	916 5'-gAT 3'	369 5'-CCT 3'
	311 5'-ggT 3'			570 5'-CCg 3'			278 5'-TgA 3'		301 5'-gTC 3'			463 5'-gCg 3'
												471 5'-gTT 3'
Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Well No.	25	26	27	28	29	30	31	32	33	34	35	36
Length of spec. PCR product	315	230	115	240	255	320	320	275	200	160	165	360
	385		195			355	395	350	255			435
						405		380	340			
Length of int. pos. control <sup>1</sup>	1070	1070	1070	1070	1070	1070	1070	1070	1070	1070	1070	<b>800</b>
5'-primer(s) <sup>2</sup>	45 5'-ggA 3'	368 5'-gTC 3'	404 5'-..g 3'	362 5'-gAC 3'	369 5'-TAC 3'	479 5'-..C 3'	488 5'-ggg 3'	2 <sup>nd</sup> I 5'-CAA 3'	2 <sup>nd</sup> I 5'-CAA 3'	419 5'-gTC 3'	412 5'-ATA 3'	45 5'-ggA 3'
			485 5'-CAA 3'			526 5'-gTC 3'	560 5'-CAC 3'					
						560 5'-CgA 3'						
3'-primer(s) <sup>3</sup>	193 5'-CgT 3'	558 5'-Agg 3'	559 5'-CAg 3'	559 5'-CAg 3'	583 5'-gTg 3'	3 <sup>rd</sup> I 5'-ATC 3'	3 <sup>rd</sup> I 5'-ATC 3'	437 5'-AAA 3'	362 5'-TCA 3'	538 5'-gTC 3'	538 5'-CCA 3'	238 5'-CCT 3'
	263 5'-gTA 3'							513 5'-TCT 3'	420 5'-gCT 3'			309 5'-gTg 3'
								544 5'-ggT 3'	505 5'-gCT 3'			
Well No.	25	26	27	28	29	30	31	32	33	34	35	36



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00



101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Well No.	37	38	39	40	41	42	43	44	45	46	47	48
Length of spec. PCR product	170	225	315	220	465	350	525	515	475	360	320	420
Length of int. pos. control <sup>1</sup>	1070	1070	<b>800</b>	1070	1070	1070	1070	1070	1070	<b>800</b>	1070	1070
5'-primer(s) <sup>2</sup>	409 5'-ggC <sup>3'</sup>	106 -CCA <sup>3'5'</sup>	45 -ggA <sup>3'5'</sup>	45 -ggA <sup>3'5'</sup>	419 -gTC <sup>3'5'</sup>	420 -TTA <sup>3'5'</sup>	357 -Tgg <sup>3'5'</sup>	369 -TAC <sup>3'5'</sup>	409 -ggC <sup>3'5'</sup>	522 -gCT <sup>3'5'</sup>	558 -ggA <sup>3'5'</sup>	463 -TgA <sup>3'</sup>
						522 5'-gCT <sup>3'</sup>			410 5'-CCA <sup>3'5'</sup>	527 -TgA <sup>3'5'</sup>	560 -CCT <sup>3'</sup>	
						539 5'-gCT <sup>3'</sup>						
3'-primer(s) <sup>3</sup>	538 5'-CCg <sup>3'5'</sup>	292 -gTC <sup>3'5'</sup>	181 -gTT <sup>3'5'</sup>	97 -gTg <sup>3'5'</sup>	3 <sup>rd</sup> I -ATC <sup>3'5'</sup>	3 <sup>rd</sup> I -ATC <sup>3'5'</sup>	3 <sup>rd</sup> I -ATC <sup>3'5'</sup>	3 <sup>rd</sup> I -ATC <sup>3'5'</sup>	3 <sup>rd</sup> I -ATC <sup>3'5'</sup>	3 <sup>rd</sup> I -ATC <sup>3'5'</sup>	3 <sup>rd</sup> I -ATC <sup>3'5'</sup>	3 <sup>rd</sup> I -ATC <sup>3'</sup>
			203 5'-CTg <sup>3'5'</sup>	302 -ggT <sup>3'</sup>								
			257 5'-CCT <sup>3'</sup>									
			267 5'-ATg <sup>3'</sup>									
Well No.	37	38	39	40	41	42	43	44	45	46	47	48

Well No.	49	50	51	52	53	54	55	56	57	58	59	60
Length of spec. PCR product	135	85	135	200	210	250	175	70	340	175	230	160
Length of int. pos. control <sup>1</sup>	1070	1070	1070	<b>800</b>	<b>800</b>	<b>800</b>	1070	1070	1070	1070	<b>800</b>	<b>800</b>
5'-primer(s) <sup>2</sup>	209 5'-ggC <sup>3'5'</sup>	463 -TgA <sup>3'5'</sup>	106 -CCA <sup>3'5'</sup>	45 -ggA <sup>3'5'</sup>	419 -gTC <sup>3'5'</sup>	45 -ggA <sup>3'5'</sup>	3 <sup>rd</sup> I -Agg <sup>3'5'</sup>	25 -CCg <sup>3'5'</sup>	400 -TCT <sup>3'5'</sup>	133 -CCA <sup>3'5'</sup>	45 -ggA <sup>3'5'</sup>	652 -CCg <sup>3'</sup>
				3 <sup>rd</sup> I 5'-Agg <sup>3'</sup>				652 5'-CCA <sup>3'5'</sup>	539 -gTg <sup>3'5'</sup>	145 -CAA <sup>3'5'</sup>	673 -CCA <sup>3'5'</sup>	661 -ACg <sup>3'</sup>
								540 5'-TgC <sup>3'</sup>			679 5'-ggC <sup>3'</sup>	
3'-primer(s) <sup>3</sup>	302 5'-ggT <sup>3'5'</sup>	506 -TgT <sup>3'5'</sup>	200 -TCA <sup>3'5'</sup>	221 -ATA <sup>3'5'</sup>	589 -CTT <sup>3'5'</sup>	127 -CTg <sup>3'5'</sup>	704 -CCA <sup>3'5'</sup>	56 -TCg <sup>3'5'</sup>	3 <sup>rd</sup> I -ATC <sup>3'5'</sup>	272 -Tgg <sup>3'5'</sup>	107 -ACT <sup>3'5'</sup>	774 -ggT <sup>3'</sup>
		608 5'-gCC <sup>3'5'</sup>	200 -TCA <sup>3'5'</sup>	723 -Tgg <sup>3'</sup>		288 5'-gTg <sup>3'5'</sup>	735 -TCg <sup>3'5'</sup>	872 -TCA <sup>3'</sup>			295 5'-TCA <sup>3'</sup>	
			239 5'-gCT <sup>3'5'</sup>	727 -CCA <sup>3'</sup>			779 5'-CTA <sup>3'</sup>				916 5'-gAT <sup>3'</sup>	
			263 5'-g <sup>3'5'</sup>	735 -TCg <sup>3'</sup>			787 5'-TCC <sup>3'</sup>					
Well No.	49	50	51	52	53	54	55	56	57	58	59	60



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Well No.	61	62	63	64	65	66	67	68	69	70	71	72
Length of spec. PCR product	160	105	175	90	405	435	265	215	130	90	290	110
			280	135	470		300	380		185	315	200
				240	520						400	295
				365								390
Length of int. pos. control <sup>1</sup>	1070	1070	1070	<b>800</b>	1070	1070	<b>800</b>	1070	1070	1070	1070	1070
5'-primer(s) <sup>2</sup>	106 5'-CCg 3' 5'	363 -AgC 3' 5'	25 -CCg 3' 5'	45 -ggA 3' 5'	363 -AAT 3' 5'	209 -ggC 3' 5'	45 -ggA 3' 5'	419 -gTC 3' 5'	209 -ggC 3' 5'	463 -TgA 3' 5'	45 -ggA 3' 5'	261 -AAC 3' 5'
	151 -gCC 3'		419 -gTC 3' 5'	679 -ggC 3' 5'	410 -gCg 3' 5'	209 -ggC 3'		668 -ggT 3'				662 -CCT 3'
				724 -g.C 3' 5'	479 -.C 3'							754 -ACg 3'
												852 -CAA 3'
3'-primer(s) <sup>3</sup>	272 -Tgg 3'	425 -CgC 3' 5'	134 -AgT 3' 5'	115 -ggA 3' 5'	3 <sup>rd</sup> I -ATC 3' 5'	353 -TgA 3' 5'	142 -ggT 3' 5'	593 -CgC 3' 5'	299 -TCA 3' 5'	510 -CAA 3' 5'	167 -ACA 3' 5'	331 -CTA 3' 5'
			554 -CCg 3' 5'	242 -CCA 3'		353 -TgA 3' 5'	177 -AAA 3' 5'	916 -gAT 3'		605 -gCT 3' 5'	189 -gCT 3' 5'	916 -gAT 3'
				774 -ggT 3'		362 -TCA 3'					277 -ggC 3'	
Well No.	61	62	63	64	65	66	67	68	69	70	71	72

Well No.	73	74	75	76	77	78	79	80	81	82	83	84
Length of spec. PCR product	155	75	280	475	185	110	215	85	395	80	255	155
		230	315		330	385	365	200		200		195
			390			475	420	225		245		235
								340				
Length of int. pos. control <sup>1</sup>	1070	<b>800</b>	1070	1070	1070	1070	<b>800</b>	1070	1070	1070	1070	1070
5'-primer(s) <sup>2</sup>	412 5'-ATA 3' 5'	368 -gTA 3' 5'	662 -CCT 3' 5'	409 -ggT 3' 5'	47 -AgT 3' 5'	97 -TCg 3' 5'	45 -ggA 3' 5'	267 -Ag 3' 5'	45 -ggA 3' 5'	106 -CCA 3' 5'	106 -CCA 3' 5'	363 -AgT 3' 5'
		523 -CCg 3' 5'	736 -gCA 3'		463 -TgA 3' 5'	400 -TCT 3'		709 -AgT 3'				404 -CCT 3'
			769 -Agg 3'			410 -gCg 3'		824 -TTg 3'				404 -.g 3'
						495 -CAC 3'		852 -CAA 3'				446 -CgT 3'
3'-primer(s) <sup>3</sup>	527 -CCT 3' 5'	559 -CAg 3' 5'	916 -gAT 3' 5'	3 <sup>rd</sup> I -ATC 3' 5'	206 -CCT 3' 5'	165 -Tgg 3' 5'	93 -AAC 3' 5'	311 -ggT 3' 5'	272 -TgT 3' 5'	146 -CCg 3' 5'	322 -gTg 3' 5'	559 -CAg 3' 5'
					605 -gCA 3' 5'	3 <sup>rd</sup> I -ATC 3' 5'	242 -CCT 3' 5'	916 -gAT 3'		263 -.g 3'		
							296 -CTT 3'			312 -AgT 3'		
Well No.	73	74	75	76	77	78	79	80	81	82	83	84



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

Well No.	85	86	87	88	89	90	91	92	93	94	95
Length of spec.	340	230	85	240	180	95	135	95	255	260	160
PCR product	395	260	295	450	240	195	325	155	295	285	340
	420	400							385	325	395
Length of int. pos. control <sup>1</sup>	1070	1070	1070	800	1070	1070	1070	1070	1070	1070	1070
5'-primer(s) <sup>2</sup>	45 5'-ggA 3' 5'	2 <sup>nd</sup> I -CAA 3'	97 -TCC 3' 5' 2 <sup>nd</sup> I	45 -ggA 3' 5'	106 -CCA 3' 5'	206 -gAC 3' 5'	45 -ggA 3' 5'	463 -TgA 3' 5'	45 -ggA 3' 5'	2 <sup>nd</sup> I -CAA 3' 5'	2 <sup>nd</sup> I -CAA 3' 5'
			5'-CAA 3'			463 5'-TgA 3' 5'			369 5'-TAC 3' 5'	767 -ggg 3' 5'	3 <sup>rd</sup> I -Agg 3'
						376 5'-gCA 3'					
3'-primer(s) <sup>3</sup>	218 5'-gCA 3' 5'	394 -gCT 3' 5'	142 -TgC 3' 5'	118 -gCT 3' 5'	247 -ATg 3' 5'	259 -CTC 3' 5'	203 -TCT 3' 5'	514 -CTg 3' 5'	135 -Ag 3' 5'	426 -TCC 3' 5'	502 -CTA 3'
	272 5'-TgT 3' 5'	426 -TCC 3' 5'	457 -gTA 3' 5'	320 -AgC 3' 5'	295 -TCA 3' 5'	616 -CgT 3' 5'	463 -gCT 3' 5'	515 -CCC 3' 5'	167 -ACA 3' 5'	487 -CgT 3' 5'	559 -CTC 3'
	296 5'-CTg 3' 5'	565 -CAT 3'		323 5'-AgA 3' 5'	320 -AgC 3'			578 5'-TgT 3' 5'	173 -TCC 3' 5'	916 -gAT 3' 5'	685 -ggT 3'
				337 5'-CTT 3'					261 5'-gTA 3'		
									585 5'-AgT 3'		
Well No.	85	86	87	88	89	90	91	92	93	94	95

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>2</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including Taq polymerase, IFU-01  
101.516-24u/04u – without Taq polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-B*15 SSP subtyping kit <sup>2</sup>																				
				Well																
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
				Prod. No.:	202239501	202239502	202239503	202239504	202239505	202239506	202239507	202239508	202239509	202239510	202239511	202239512	202239513	202239514	202239515	202239516
IHC cell line <sup>1</sup>		B*																		
1	9001 SA	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707	*52:01	*73:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
3	9011 E4181324	*52:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373	*15:10	*53:01	-	-	-	-	+	-	+	-	-	-	-	-	+	+	-	-	-
5	9009 KAS011	*37:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM	*39:01	*51:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020 QBL	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU	*35:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3	*54:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT	*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB	*57:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM	*27:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA	*15:01	*15:20	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075 DKB	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007	*40:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540	*08:01	*55:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367	*14:01	*56:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA	*15:01		+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE	*35:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL	*40:02	*56:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9	*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49	*58:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007	*07:05	*51:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	9320 BEL5GB	*44:02	*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU	*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH	*42:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG	*41:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO	*44:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17	*15:01	*35:01	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL	*15:01		+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML	*08:01	*27:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199	*13:02	*46:01	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301	*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089	*46:01		-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526	*46:01		-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057 TEM	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO	*42:01	*50:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO	*51:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND	*35:01	*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-



0197

For In Vitro Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00

101.516-24/04 – including Taq polymerase, IFU-01  
 101.516-24u/04u – without Taq polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

<b>CELL LINE VALIDATION SHEET</b>																				
<b>HLA-B*15 SSP subtyping kit<sup>2</sup></b>																				
				Well																
				Prod. No.:																
				202239517	202239518	202239519	202239520	202239521	202239522	202239523	202239524	202239525	202239526	202239527	202239528	202239529	202239530	202239531	202239532	
IHC cell line <sup>1</sup>		B*																		
1	9001 SA	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707	*52:01	*73:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
3	9011 E4181324	*52:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373	*15:10	*53:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
5	9009 KAS011	*37:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM	*39:01	*51:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
7	9020 QBL	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
8	9025 DEU	*35:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3	*54:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT	*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB	*57:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM	*27:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA	*15:01	*15:20	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
15	9075 DKB	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007	*40:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540	*08:01	*55:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367	*14:01	*56:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
20	9059 SLE005	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA	*15:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE	*35:03		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL	*40:02	*56:02	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9	*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49	*58:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007	*07:05	*51:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
28	9320 BEL5GB	*44:02	*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU	*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH	*42:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
32	9297 HAG	*41:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO	*44:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17	*15:01	*35:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL	*15:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML	*08:01	*27:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199	*13:02	*46:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301	*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089	*46:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526	*46:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
44	9057 TEM	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO	*42:01	*50:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO	*51:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND	*35:01	*44:03	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-



0197

For In Vitro Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-B*15 SSP subtyping kit <sup>2</sup>																				
				Well																
				33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	
				Prod. No.:	202239533	202239534	202239535	202239536	202239537	202239538	202239539	202239540	202239541	202239542	202239543	202239544	202239545	202239546	202239547	202239548
IHCW cell line <sup>1</sup>		B*																		
1	9001	SA	*07:02		-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
2	9280	LK707	*52:01	*73:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011	E4181324	*52:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275	GU373	*15:10	*53:01	-	-	-	-	-	-	-	-	-	+	-	+	+	+	+	+
5	9009	KAS011	*37:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353	SM	*39:01	*51:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020	QBL	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025	DEU	*35:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026	YAR	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107	LKT3	*54:01		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
11	9051	PITOUT	*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052	DBB	*57:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004	JESTHOM	*27:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071	OLGA	*15:01	*15:20	-	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+
15	9075	DKB	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037	SWEIG007	*40:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282	CTM3953540	*08:01	*55:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
18	9257	32367	*14:01	*56:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
19	9038	BM16	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059	SLE005	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064	AMALA	*15:01		-	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+
22	9056	KOSE	*35:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124	IHL	*40:02	*56:02	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
24	9035	JBUSH	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049	IBW9	*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285	WT49	*58:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191	CH1007	*07:05	*51:01	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
28	9320	BEL5GB	*44:02	*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050	MOU	*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021	RSH	*42:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019	DUCAF	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297	HAG	*41:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098	MT14B	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104	DHIF	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302	SSTO	*44:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024	KT17	*15:01	*35:01	-	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+
37	9065	HHKB	*07:02		-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
38	9099	LZL	*15:01		-	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+
39	9315	CML	*08:01	*27:05	-	-	-	-	-	W	-	-	-	-	-	-	-	-	-	-
40	9134	WHONP199	*13:02	*46:01	-	-	-	-	-	+	-	-	+	-	-	+	+	+	+	+
41	9055	H0301	*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066	TAB089	*46:01		-	-	-	-	-	+	-	-	+	-	-	+	+	+	+	+
43	9076	T7526	*46:01		-	-	-	-	-	+	-	-	+	-	-	+	+	+	+	+
44	9057	TEM	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239	SHJO	*42:01	*50:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013	SCHU	*07:02		-	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-
47	9045	TUBO	*51:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303	TER-ND	*35:01	*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-B*15 SSP subtyping kit <sup>2</sup>																				
				Well																
				49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	
				Prod. No.:	202239549	202239550	202239551	202239552	202239553	202239554	202239555	202239556	202239557	202239558	202239559	202239560	202239561	202239562	202239563	202239564
	IHWC cell line <sup>1</sup>		B*																	
1	9001 SA		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707		*52:01	*73:01	-	-	-	-	-	-	+	-	-	-	-	+	-	-	-	-
3	9011 E4181324		*52:01		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
4	9275 GU373		*15:10	*53:01	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
5	9009 KAS011		*37:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM		*39:01	*51:01	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
7	9020 QBL		*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU		*35:01		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
9	9026 YAR		*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3		*54:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT		*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB		*57:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM		*27:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA		*15:01	*15:20	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
15	9075 DKB		*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007		*40:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540		*08:01	*55:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367		*14:01	*56:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16		*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005		*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA		*15:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE		*35:03		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
23	9124 IHL		*40:02	*56:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH		*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9		*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49		*58:01		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
27	9191 CH1007		*07:05	*51:01	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
28	9320 BEL5GB		*44:02	*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU		*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH		*42:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF		*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG		*41:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B		*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF		*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO		*44:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17		*15:01	*35:01	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
37	9065 HHKB		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL		*15:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML		*08:01	*27:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199		*13:02	*46:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301		*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089		*46:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526		*46:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057 TEM		*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO		*42:01	*50:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO		*51:01		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-
48	9303 TER-ND		*35:01	*44:03	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00



101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-B*15 SSP subtyping kit <sup>2</sup>																				
				Well																
				65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	
				Prod. No.:	202239565	202239566	202239567	202239568	202239569	202239570	202239571	202239572	202239573	202239574	202239575	202239576	202239577	202239578	202239579	202239580
	IHWC cell line <sup>1</sup>		B*																	
1	9001 SA		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707		*52:01	*73:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
3	9011 E4181324		*52:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
4	9275 GU373		*15:10	*53:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	9009 KAS011		*37:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM		*39:01	*51:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
7	9020 QBL		*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU		*35:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR		*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3		*54:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT		*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB		*57:01		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM		*27:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA		*15:01	*15:20	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075 DKB		*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007		*40:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540		*08:01	*55:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
18	9257 32367		*14:01	*56:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16		*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005		*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA		*15:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE		*35:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL		*40:02	*56:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH		*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9		*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49		*58:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007		*07:05	*51:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
28	9320 BEL5GB		*44:02	*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU		*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH		*42:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF		*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG		*41:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B		*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF		*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO		*44:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17		*15:01	*35:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL		*15:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML		*08:01	*27:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199		*13:02	*46:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301		*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089		*46:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526		*46:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057 TEM		*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO		*42:01	*50:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU		*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO		*51:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
48	9303 TER-ND		*35:01	*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

CELL LINE VALIDATION SHEET																	
HLA-B*15 SSP subtyping kit <sup>2</sup>																	
			Well														
			81	82	83	84	85	86	87	88	89	90	91	92	93	94	95
			Prod. No.:														
			202239581	202239582	202239583	202239584	202239585	202239586	202239587	202239588	202239589	202239590	202239591	202239592	202239593	202239594	202239595
	IHWC cell line <sup>1</sup>	B*															
1	9001 SA	*07:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707	*52:01	*73:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-
3	9011 E4181324	*52:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-
4	9275 GU373	*15:10	*53:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	9009 KAS011	*37:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-
6	9353 SM	*39:01	*51:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020 QBL	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU	*35:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3	*54:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT	*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB	*57:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM	*27:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGGA	*15:01	*15:20	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075 DKB	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007	*40:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540	*08:01	*55:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367	*14:01	*56:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA	*15:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE	*35:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL	*40:02	*56:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9	*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49	*58:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007	*07:05	*51:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	9320 BEL5GB	*44:02	*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU	*44:03		-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH	*42:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF	*18:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG	*41:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B	*40:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO	*44:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17	*15:01	*35:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL	*15:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML	*08:01	*27:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199	*13:02	*46:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301	*14:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089	*46:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526	*46:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057 TEM	*38:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO	*42:01	*50:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU	*07:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO	*51:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND	*35:01	*44:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
 101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

**Lot No.: 9N3**

**Lot-specific information**

<sup>1</sup>The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

<sup>2</sup>The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 4, 9, 10, 18, 24 to 27, 30 to 34, 36, 39, 49 to 54, 56 to 59, 61 to 65, 67 to 72, 74, 75, 78 to 80, 82 to 89 and 91 to 95 were available. The specificities of the primers in primer solutions 9, 10, 18, 24 to 27, 30, 31, 33, 34, 36, 49, 53, 59, 61, 63 to 65, 67, 68, 70 to 72, 78, 82, 85, 87, 91 and 93 to 95 were tested by separately adding one or two additional 5'-primers, respectively one to three additional 3'-primers. In primer solutions 4, 32, 39, 50 to 52, 54, 56, 62, 69, 79, 83, 86, 88, 89 and 92 it was only possible to test the 5'-primers, the 3'-primers were not possible to test. In primer solutions 57, 58, 74, 75, 80 and 84 it was only possible to test the 3'-primers, the 5'-primers were not possible to test. In primer solutions 1, 3, 12, 13, 19, 21, 24, 25, 33, 36, 55, 59, 63, 64, 67, 68, 70 to 72, 77, 82, 85, 87, 90, 91, 93 to 95 one or more 3'-primers were not possible to test. In primer solutions 10, 14, 20, 22, 27, 30, 31, 42, 45 to 47, 59 to 61, 64, 65, 72, 77, 91 and 94 one, two or three 5'-primers were not possible to test. In addition, the primers in primer solutions 16, 40, 42, 66, 77 and 90 were tested by separately adding one additional 5'-primer or one additional 3'-primer.



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: May 2022, Rev. No: 00

101.516-24/04 – including *Taq* polymerase, IFU-01  
101.516-24u/04u – without *Taq* polymerase, IFU-02

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **9N3**

Lot-specific information

**ADDRESSES:**

**Manufacturer:**

**CareDx AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00

**Fax:** +46-8-717 88 18

**E-mail:** [orders-se@caredx.com](mailto:orders-se@caredx.com)

**Web page:** [www.caredx.com](http://www.caredx.com)

**Distributed by:**

**CareDx Lab Solutions Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-653-78171

**Fax:** 610-344-7989

**E-mail:** [orders-us@caredx.com](mailto:orders-us@caredx.com)

**Web page:** [www.caredx.com](http://www.caredx.com)

For information on CareDx distributors worldwide, contact **CareDx AB**.



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: May 2022, Rev. No: 00